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ABSTRACT 
 
Sequencing of tumor genomes has shown that many loss-of-function alterations exist in cancer 
cells.  Some of these alterations are a product of the cancerous progression of such cells, while 
others play a causative role.  Unlike gain-of-function or overexpression alterations, these loss-
of-function alterations are difficult to target directly, meaning that alternative approaches are 
necessary.  In this case, such alterations can be specifically targeted through utilizing synthetic 
lethal interactions, whereby simultaneous inhibition of a particular interacting partner gene 
causes lethality in the context of a previously inactivated gene.  Such a loss-of-function 
alteration occurs in the case of the EPHB6 receptor tyrosine kinase, which is downregulated in 
multiple cancer types. This downregulation of EPHB6, along with its inherent anti-malignant 
properties, make it a logical target for the synthetic lethal approach.  In my thesis, I describe the 
use of a large-scale genome-wide screen of EPHB6 in triple-negative beast caner cells to 
determine corresponding synthetic lethal genes, which may be therapeutically targeted.  The 
screen revealed the SRC kinase as a synthetic lethal partner of EPHB6, whereby targeting of 
SRC in EPHB6-deficient cells results in lethality.  In addition, small molecule SRC inhibitors, 
such as KX2-391, were used to improve elimination of EPHB6-deficient triple-negative breast 
cancer cells in both monolayer culture, as well as in xenograft tumor models.  This work 
reveals EPHB6 to be a biomarker for the use of SRC inhibitors in triple negative breast cancer, 
and it contributes to larger synthetic lethal interaction maps of cancer as a whole. 
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1.0 Introduction 
1.1 Breast Cancer Subtypes 
  According to data collected by the International Agency for Research on Cancer, breast 
cancer is the most common cancer among women (Ferlay et al., 2015).  In data from 2012, 
there were an estimated 1.67 million new diagnosed cases of breast cancer, with an estimated 
522,000 deaths worldwide.  While in Canada, about 25,000 new cases of breast cancer are 
being diagnosed per year, according to the Canadian Cancer Society 
(http://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics).  In addition, it is the 
most common cause of cancer-related death among women in developing countries, while in 
developed countries it ranks as the second most common, after lung cancer.  As such, extensive 
research has been directed toward its treatment in the past decades.  Breast cancer is divided 
into different subtypes, each of which has its own unique, biological differences (Table 1.1).  
These subtypes were determined largely based on the expression of particular genes, such as the 
estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor.  In a study by Perou et 
al. (2000), the variation of gene expression was elucidated from 65 different breast tumor 
samples.  This study used complimentary DNA microarrays in order to assess the expression of 
8,102 different human genes.  This data was then organized by cluster analysis, whereby it 
revealed several clear divisions in gene expression based on tumor type.  Those tumors 
determined to be ER positive were also found displaying a high expression level of many genes 
associated with breast luminal tissue, which was confirmed by immunohistochemistry.  
However, tumors of breast basal tissue origin lacked expression of both ER and genes that are 
normally co-expressed with ER. 
 
Table 1.1  Breast cancer subtypes 
Breast cancer 
subtype Luminal A Luminal B HER2 Triple negative 
Receptor expression ER+, PR+, and HER2- 
ER+, PR+, and 
HER2+ 
ER-, PR-, and 
HER2+ 
ER-, PR-, and 
HER2- 
Incidence of subtype 50-60% 15-20% 15-20% 10-20% 
 
The most common breast cancer subtype is luminal breast cancer, which is, in turn, 
divided into luminal A and luminal B types.  These tumors, accounting for ~75% of all breast 
cancer, express ER and PR, as well as many other genes consistent with breast luminal tissue 
	 2	
(Perou et al., 2000; Vallejos et al., 2010; Yersal and Barutca, 2014).  In addition to ER and PR, 
luminal B breast cancer is also known to express the HER2 receptor.  Luminal breast cancer 
tumors are typically associated with a good prognosis, with luminal A being significantly more 
favorable than luminal B (Sørlie et al., 2001).  Typically, luminal tumors are more responsive 
to hormone therapy than they are to chemotherapy (Brenton et al., 2005).  The HER2 subtype, 
accounting for 15-20% of breast cancer cases, carries a less favorable prognosis, and is 
characterized by high expression of the HER2 receptor, but no expression of ER or PR (Yersal 
and Barutca, 2014; Dai et al., 2015).  The less favorable prognosis of HER2 breast cancer is 
largely due to the higher chance of relapse in patients that have not experienced a full 
elimination of tumors (Brenton et al., 2005).  However, due to the expression of HER2 in this 
subtype, treatment is possible with trastuzumab, which is an anti-HER2 monoclonal antibody.  
Lastly, the triple negative breast cancer (TNBC) subtype is characterized by the lack of ER and 
PR expression and does not overexpress the HER2 receptor (Dai et al., 2015).  TNBC accounts 
for 10-20% of breast cancer cases and is associated with a very high rate of patient mortality 
due to the complete absence of targeted therapies (Boyle, 2012; Mayer et al., 2014).  Therefore, 
there is an active search for efficient therapeutic targets that would allow treatment 
personalization in TNBC tumors.  In particular, some members of the Eph family of receptor 
tyrosine kinases have been viewed as promising targets for breast cancer therapy. 
 
1.2 Eph Receptors 
The Eph family of receptor tyrosine kinases is represented by sixteen members, divided 
into two groups based on the ligands to which they bind (Truitt and Freywald, 2011).  Their 
ligands, ephrins, are divided into ephrin-A and ephrin-B groups based on their molecular 
structures.  The ephrin-A members, consisting of ephrin-A1 to ephrin-A6, are cell membrane 
proteins with GPI anchors, while the ephrin-B members, consisting of ephrin-B1 to ephrin-B3, 
have transmembrane and cytoplasmic domains (Figure 1.1).  Therefore, the Eph receptors are 
classified as either EphAs, consisting of EPHA1 to EPHA10, which mostly bind ephrin-A 
ligands, or as EphBs, consisting of EPHB1 to EPHB6, which mostly bind ephrin-B ligands 
(Pasquale, 2008).  
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Figure 1.1  Eph receptors and ephrin ligands 
This figure shows EphA and EphB receptors, with their typical ligands, ephrin-A and ephrin-B, 
respectively. Upon interaction with the ephrin ligands, the Eph receptor’s kinase domain is 
converted to its active form.  The Eph receptor can then phosphorylate tyrosine residues, 
thereby generating, or even suppressing signaling cascades in the cell. Further interactions with 
surrounding proteins may also be mediated by the SAM and PDZ domains.  However, most 
Eph receptor signaling is mediated by phosphotyrosines (Pasquale, 2005).  Additionally, 
ephrins are also capable of generating a signaling event following interaction, referred to as 
reverse signaling. 
 
 
 While EphA receptors mostly interact with ephrin-A ligands and EphB receptors mostly 
interact with ephrin-B ligands, within each group ligand-receptor interactions are quite broad, 
with most EphA receptors binding to any ephrin-A ligand and most EphB receptors binding to 
any ephrin-B ligand.  Some Eph receptors however, are stricter in their binding, such as 
EPHB6, which has been reported to only bind ephrin-B1 and ephrin-B2, and not ephrin-B3 
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(Munthe et al., 2000; Freywald et al., 2002).  Eph receptors are involved in a number of 
different processes through their basal or ligand-induced signaling, including embryo 
development (Poliakov et al., 2004) and the maintenance of homeostasis in multiple systems of 
adult organisms (Holmberg et al., 2006).  This is in keeping with the Eph receptor ability to 
regulate multiple responses in different types of stem cells, including both adult and cancer 
stem cell populations (Holmberg et al., 2006; Chumley et al., 2007; Stokowski et al., 2007). 
Like other receptor tyrosine kinases, Eph receptors are activated by interactions with their 
ligands, leading to receptor dimerization or oligomerization, and phosphorylation of tyrosine 
residues (Himanen et al., 2007).  This phosphorylation enhances Eph receptor activity and 
increases interactions with cytoplasmic signaling molecules, thereby initiating signaling 
pathways in the cytoplasm (Murai and Pasquale, 2003).  Interestingly though, both EphA and 
EphB receptor groups possess members which are kinase-deficient, EPHA10 and EPHB6, 
indicating that these receptors may be important for ephrin-induced responses (Truitt and 
Freywald, 2011).  However, it has also been shown that these kinase-dead receptors are able to 
form complexes with other surface proteins, thereby allowing signaling to occur through an 
alternate route.  This can be observed in the case of EPHB6, which is able to interact with other 
Eph receptors, such as EPHB1 and EPHB4, as well as with other proteins, such as c-CBL and 
the SRC family kinase FYN (Freywald et al., 2002; Matsuoka et al., 2005; Truitt et al., 2010). 
 
1.3 Eph Receptors and Cancer 
Increasing evidence has suggested that EphB receptors and their ligands play an 
important role in cancer activity (Truitt et al., 2010).  EphB receptors have been associated with 
malignancies in a number of examples of their overexpression and even causal involvement in 
oncogenesis (Lugli et al., 2005).  EPHB2 in particular, is often overexpressed in metastatic 
breast carcinomas (Fox and Kandpal, 2004), while EPHB4 enhances the growth of breast 
tumors (Kumar et al., 2006).  In fact, EPHB4 has been shown to be involved in cancer invasion 
and metastasis in a number of ways.  High expression of EPHB4 is considered to be an early 
event in the progression of prostate cancer.  Additionally, it has been shown that EPHB4 is able 
to contribute to increased motility in prostate cancer cells through its regulation of integrin ß8, 
whereby high levels of EPHB4 expression also correlated with high integrin ß8 levels 
(Mertens-Walker et al., 2015).  
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While there is strong evidence for Eph receptors such as EPHB4 acting to promote 
cancer, other Eph receptors such as EPHB6 tend to show a different effect.  In fact, a strong 
negative correlation has been determined between breast cancer aggressiveness and the 
receptor, with reduced EPHB6 activity being noted in cases of aggressive breast cancer (Fox 
and Kandpal, 2004).  For example, through interaction with c-CBL, EPHB6 mediates the 
activation of the cytoskeleton regulator, ABL (Truitt et al., 2010).  Although in this work a 
direct CBL-ABL complex could not be detected, this study showed that silencing of c-CBL 
resulted in the inability of EPHB6 to successfully initiate ABL phosphorylation, resulting in a 
further failure to inhibit morphological changes leading to invasion.  This is understandable, as 
in addition to its function as an E3-ubiquitilase, c-CBL has been shown to act as an adaptor, 
linking cell surface receptors to signaling proteins in the cytoplasm, thus regulating cytoskeletal 
arrangement (Swaminathan and Tsygankov, 2006).  In this way, EPHB6 signaling is able to 
promote cell adhesion, thereby reducing invasiveness of cancer cells (Figure 1.2).  To this end, 
studies such as those involving neuroblastomas have shown that a high expression level of 
EPHB6 is indicative of a lower tumor stage, while more advanced malignancies have been 
shown to express lower levels of EPHB6 (Truitt and Freywald, 2011).  In addition, through the 
use of reverse transcriptase-PCR, it has been shown that EPHB6 expression is able to reduce 
production of matrix metalloproteinase(MMP)7 and MMP19, in breast cancer cells (Fox and 
Kandpal, 2009).  While the mechanism of this EPHB6 action is currently unclear, the 
observation is important due to the ability of MMPs to promote cell invasive capabilities 
through degradation of the extracellular matrix.  Furthermore, other studies have revealed that 
EPHB6 promotes anoikis in breast cancer cells, while loss of EPHB6 expression promotes a 
resistance to anoikis (Akada et al., 2014).  Therefore, it can be seen that EPHB6 not only 
suppresses invasive phenotypes, but also acts to eliminate cells that become detached. 
Because EPHB6 acts in different ways to suppress cancerous activities, it makes sense 
that its expression would be low, or even lost in cancer cells.  In fact, EPHB6 is consistently 
downregulated in various malignancies, including metastatic lung cancer (Muller-Tidow et al., 
2005), melanoma (Hafner et al., 2003), prostate cancer (Mohamed et al., 2015), ovarian 
carcinoma (Gu et al., 2016), gastric cancer (Liersch-Lohn et al., 2016), aggressive 
neuroblastoma (Tang et al., 1999; Tang et al., 2000), and invasive breast cancer cell lines (Fox 
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and Kandpal, 2004; Fox and Kandpal, 2006).  All of these findings suggest that there is an 
important role for the EPHB6 receptor in malignancy.	
 
 
 
Figure 1.2  EPHB6 signals through c-CBL to suppress cancer invasion and migration 
EPHB6 is kinase dead, and it often relies on interactions with other proteins in order to signal.  
In one such situation, EPHB6 interacts with c-CBL, which results in c-ABL phosphorylation, 
leading to suppression of invasion and migration. A direct CBL-ABL complex was not 
detected, but silencing of either CBL or ABL alone decreased EPHB6’s ability to inhibit 
invasion and migration, thereby indicating an important role for the EPHB6-CBL-ABL 
signaling pathway in suppressing cancer invasiveness. 
 
 
Despite the fact that overexpression of many EphB receptors often supports cancer 
aggressiveness, EPHB6 acts in an opposite fashion by consistently suppressing malignant 
activities.  This agrees with EPHB6’s unusual properties, as it is a catalytically inactive Eph 
receptor due to alterations in its kinase domain.  Importantly, these alterations include 
replacement of lysine with a glutamine residue in the VAIK motif of kinase subdomain II, as 
well as replacement of aspartic acid with a serine residue in the HRD sequence of the 
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phosphotransfer site of subdomain VI (Gurniak and Berg, 1996; Matsuoka et al., 1997).  
Because of this, EPHB6 must initiate signaling by interacting with other EphB receptors to 
assure its phosphorylation (Truitt and Freywald, 2011).  In fact, though many other Eph 
receptors are capable of promoting migration and invasion, regulation by EPHB6 has been 
found to reverse these effects.  It	 has	 been	 shown	 that	 EPHB4	 has	 a	 role	 in	 the	phosphorylation	of	EPHB6,	to	the	degree	that	inhibition	of	EPHB4	results	in	a	blockage	of	EPHB6	phosphorylation	(Truitt	et	al.,	2010).		This	means	that	EphB6	resides	in	a	system	where,	to	a	degree,	it	utilizes	activated	EPHB4	in	order	to	function	properly.		This	means	that	 EPHB6	 has	 an	 important	 role	 in	 regard	 to	 its	 interactions	 with	 EPHB4	 (Pasquale,	2010).	 	EPHB6	activation	often	leads	to	a	decrease	of	 invasiveness	through	its	signaling,	which	means	that	it	essentially	reverses	the	overexpression	activity	of	EPHB4	and	other	invasion-promoting	receptors.	 	 It	has	been	shown	that	 in	 the	absence	of	EPHB6,	EPHB4	will	continue	to	promote	invasion	(Truitt	et	al.,	2010)	(Figure	1.3).		This	reveals	a	balance	that	 exists	 between	 the	 two	 receptors,	 as	 both	 have	 their	 own	 important	 role.	 	 But	 it	should	be	noted	that	in	this	balance,	the	level	of	EPHB6	expression	is	very	important,	as	it	has	the	ability	to	turn	EPHB4	from	its	otherwise	invasion-promoting	activities.		 	
1.4 Synthetic Lethality 
The correlation of decreasing EPHB6 activity with increasing cancer aggressiveness 
suggests that mutation or suppression of the ephB6 gene could play an important role in 
malignant activity, meaning that the loss of EPHB6 could potentially be targeted for therapeutic 
strategies.  However, because EPHB6 expression is lost, it becomes difficult to target directly, 
since there is no functional product that therapy can be directed toward.  This means that an 
alternative approach must be taken.  In recent years, efforts toward development of new 
anticancer drugs have lead to exploitation of the interactions between gene pairs, which can 
reveal their phenotypic relationships (Dixon et al., 2009).  In broad terms, these genetic 
interactions can be classified either as negative genetic interactions (NGIs) that cause fitness 
defects, or as positive genetic interactions (PGI) that lead to growth and survival.  Most 
phenotypic traits of cancer are caused by genetic alterations, including both gain-of-function 
mutations and loss-of-function mutations.  Gain-of-function mutations can involve 
amplification or overactivation of proto-oncogenes, whereas loss-of-function mutations, such as 
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the loss of EPHB6, can be due to deletion or even epigenetic silencing of tumor suppressors.  In 
the case of such alterations, NGIs that lead to fitness defects can be exploited for targeted 
therapy through an approach known as synthetic lethality (SL) (Paul et al., 2014).  Two genes 
are determined to cause SL when an inactivating mutation in either gene alone leaves the cell 
viable, but when inactivated together, they cause cell death (Dixon et al., 2009) (Figure 1.4).  It 
is generally understood that gene interactions are often functional and maybe even work in 
parallel cellular pathways.  However, there is plasticity in the biological networks of cancer 
cells, meaning that genetic dependency may arise from previously unexpected pathways.  
Therefore, new possibilities of NGIs may arise in a situation referred to as ‘induced 
essentiality’ (Tischler et al., 2008). 
 
Figure 1.3  Interaction of EPHB6 and EPHB4 affects cancer metastasis 
Though EPHB4 has been found acting to promote invasion and migration in many cancer cells, 
interaction with EPHB6 inhibits invasion and migration, thereby inhibiting metastasis. 
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Figure 1.4  Synthetic lethality between two genes 
Synthetic lethality occurs between two genes when suppression of one gene causes cell or 
organismal death only when the other gene is also inactivated. 
 
 
Because EPHB6 expression is lost in many malignancies, it is likely that other genes may 
be found that exhibit a SL relationship with EPHB6.  These could be genes that act in parallel 
pathways, or even interact directly with EPHB6 itself, whereby targeting of such gene partners 
could result in a NGI and subsequent loss of fitness in such cancer cells.  This means that the 
next step toward taking advantage of EPHB6 loss is to determine a list of SL gene partners.  In 
this regard, there are several approaches that have been used.  A classical approach involves the 
use of model organisms to make inferences about NGI in humans.  For example, information 
collected from the yeast Saccharomyces cerevisiae can be used to identify gene interactions in 
humans, provided that the genes and their functions are conserved (Hartwell et al., 1997) 
(Figure 1.5).  Such use of model organisms has successfully predicted conserved SL 
interactions, such as the relationship observed between RAD54B and SOD1, wherein inhibition 
of SOD1 lead to apoptosis in RAD54B-deficient colorectal cancer cells (Sajesh et al., 2013).  
However, this method alone is not sufficient to comprehensively define human SL interactions, 
as only a portion of human genes can be mapped from organisms such as Saccharomyces 
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cerevisiae.  Additional NGIs may be determined through years of experimental knowledge that 
have been accumulated.  For example, work by Gurley and Kemp has successfully used mice to 
demonstrate SL interactions between ATM and DNA-PK, which are both genes known to be 
frequently mutated in cancer (Gurley and Kemp, 2001).  Such a knowledge base will only 
continue to grow, providing further examples of NGIs that can be exploited for therapeutic 
solutions to loss-of-function mutations.  However, to gain a comprehensive understanding of 
the many possible SL interactions that might occur with EPHB6 loss, it is important to take a 
more thorough approach. 
 
 
 
Figure 1.5  Predicting negative genetic interactions using model systems 
If two genes are found to display a negative genetic interaction (NGI) in one species, such as 
yeast, then it may be possible that the corresponding orthologous human genes may display a 
similar NGI. 
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1.5 Pooled Screening for Synthetic Lethal Interactions 
Pooled screening is a broad approach that is capable of providing NGI data for thousands 
of genes simultaneously.  Originally, pooled screening emerged from strategies used to define 
genetic interactions in yeast collections, where growth defects were evaluated in a pool of yeast 
based on barcodes that had been incorporated into them (Pan et al., 2007).  This process utilized 
transduction of cells with pooled lentiviral particles, which express unique sequences of short 
hairpin RNA (shRNA) that can be integrated into the genome, and which could then be 
quantitated like a barcode (Vizeacoumar et al., 2013).  Because there is often genetic drift in 
human cancer cells, the use of isogenic cell lines is an ideal way to assess specific interactions 
associated with the alteration of a single molecule.  The isogenic cell lines are transduced with 
shRNAs, which are then incorporated, and the cells are cultured to allow for SL effects to 
occur.  The SL interaction can then be quantified by amplifying the barcode sequences from a 
single mixture of genomic DNA using universal primers.  The abundance of each sequence can 
then be measured using barcode microarrays (Figure 1.6).  The loss of specific sequences 
within a mutated cell population, when compared to the isogenic parental control, would 
identify which shRNA targets are SL.  Therefore, in the case of EPHB6, two isogenic cell lines 
could be generated, whereby one expresses EPHB6 and one does not.  Following microarray 
deconvolution, SL effects could be compared between the two cell lines based on the 
abundance of shRNAs retrieved from the genomic DNA. 
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Figure 1.6  Pooled screening overview 
Graphical representation showing the steps of the shRNA pooled screening pipeline.  A pooled 
shRNA library, encoded in lentiviral vectors, is applied to isogenic cell lines that differ in a 
mutation of interest.  The cells are passaged over multiple generations and genomic DNA from 
several time points is analyzed by microarray deconvolution.  shRNAs that drop out in both cell 
lines identify essential genes, while shRNAs that drop out only in the mutated cell line identify 
genes that display a negative genetic interaction (NGI) with that mutation. 
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An extended application of the pooled screening format in cancer target identification is 
its application in chemical genetics.  Predicting which combination of drugs will work 
successfully in therapy remains a major challenge.  Such trials are expensive, time consuming, 
and often not rationally designed. To circumvent these limitations, pooled screens offer the 
unprecedented advantage to systematically search for targets that would act synergistically with 
a clinically approved drug (Bajrami et al., 2014).  For example, a clinically approved EGFR 
inhibitor, cetuximab, efficiently treats patients with cancer who harbor activating mutations in 
EGFR. However, patients carrying activating mutations in both EGFR and KRAS will not 
respond to cetuximab treatment alone due to the EGFR-independent activation of KRAS 
effector pathways.  Determination that the cell surface receptor CD83 exhibits NGI with both 
KRAS and cetuximab treatment offers a new therapeutic opportunity (Vizeacoumar et al., 
2013).  Such targets can be examined with a much higher degree of confidence for a positive 
response.  Ideally, in the application of SL to the discovery of cancer drugs, the main goal 
would be to identify target genes which, when either mutated or inhibited, would kill cells 
containing a specific cancer-related alteration but would otherwise spare identical healthy cells 
lacking such an alteration.  Therefore, in the context of low expression of EPHB6, the 
identification of a corresponding SL gene would be therapeutically advantageous. 
 
1.6 Building Genetic Interaction Maps 
Targeting strategies such as large-scale pooled screening do not depend on aspects such 
as tissue specificity, but instead are dependent on genetically determined differences between 
normal and cancerous tissue.  However, these differences embodied by tumor genetics are not 
due to routine genetic redundancies.  The situation in which cancer cells continue to undergo 
mutations as a part of their malignant evolution forces them to genetically depend on 
compensatory alternative pathways, resulting in a deviation from the standard redundancies.  
Therefore, it is essential to develop a blueprint of the cellular circuitry in order to understand 
the genetic dependencies of various cancer cells.  Previously, researchers studying yeast 
adopted an epistatic mini array profile (E-MAP) approach, in which they focused on 
functionally related genes rather than taking a whole genome approach (Collins et al., 2007).  
Such an approach results in the construction of high-density maps for a given biological process 
revealing specific molecular interactions (Bassik et al., 2013; Roguev et al., 2013).  Similarly, 
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recent methods to map interactions in human cells are just beginning (Liberali et al., 2014), and 
building a map of the cancer genome requires an E-MAP style concerted effort from the cancer 
genomics community.  In fact, a large-scale data-driven study has recently demonstrated that 
SL networks can predict gene essentiality, clinical prognosis of patient survival, and even drug 
response (Choung et al., 2014).  Tumor sequencing has shown that there is only a limited set of 
genes that are typically altered in the majority of tumors (Wood et al., 2007; Vogelstein et al., 
2013).  This means that creating a detailed classification of different malignancies based on 
their genetic causes, as well as generating a complete interactome of these genetic lesions could 
yield a much more accurate understanding and identification of therapeutic targets.  Such a 
strategy depends on building an overall map of cancer cell interactions, which holds promise 
for personalized medicine.  Therefore, large-scale pooled screens of individual gene expression, 
such as the EPHB6 screen carried out in this study, are necessary for a piecewise construction 
of such an interaction map. 
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2.0 Hypothesis and Objectives 
 
2.1 Hypothesis 
As EPHB6 is frequently downregulated in breast cancer malignancies, we hypothesize that the 
loss of EPHB6 will represent new, efficient therapeutic targets, based on its synthetic lethal 
interactions. 
 
2.2 Objectives 
1. Identification of synthetic lethal interactions associated with the absence of EPHB6 
expression.  
2. Validation of synthetic lethal interactions and rationalization of target selection. 
3. Testing of selected target genes in cell lines and xenograft tumors. 
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3.0 Materials and Methods 
3.1 Uncommon Reagents 
 
Table 3.1  Uncommon reagents 
Reagent Supplier 
7-Aminoactinomycin D (7-AAD) BD Biosciences (Mississauga, ON, Canada) 
Anti-C-SRC Santa Cruz Biotechnology (Dallas, TX, USA)  
Anti-phospho-SRC  Life Technologies (Burlington, ON, Canada)   
Anti-β-tubulin Santa Cruz Biotechnology (Dallas, TX, USA)  
Bovine serum albumin (BSA) BioShop Canada Inc. (Burlington, ON, Canada) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (St. Louis, MO, USA) 
FITC-conjugated anti-sheep 
secondary antibody R&D Systems (Minneapolis, MN, USA) 
Human anti-EPHB6 antibody R&D Systems (Minneapolis, MN, USA) 
KX2-391 Selleckchem (Houston, TX, USA) 
Polybrene Sigma-Aldrich (St. Louis, MO, USA) 
Propidium iodide (PI) ThermoFisher Scientific (Burlington, ON, Canada) 
Puromycin ThermoFisher Scientific (Burlington, ON, Canada) 
Resazurin R&D Systems (Minneapolis, MN, USA) 
Sheep IgG control antibody R&D Systems (Minneapolis, MN, USA) 
SU6656 Santa Cruz Biotechnology (Dallas, TX, USA)  
 
 
3.2 Expression Analysis and Methylation Box-and-Whisker Plots 
3.2.1 Data Collection 
Expression data from The Cancer Genome Atlas (TCGA) datasets for different cancer 
types was collected in regard to both EPHB6 and SRC.  The distribution was plotted for both 
tumor patients and normal patients.  TCGA methylome data was also collected for EPHB6 and 
the distribution was plotted for both tumor patients and normal patients. 
 
3.2.2 Interpretation of Box-and-Whisker Plot Data 
 Data from TCGA, whether of expression or methylation, was organized into box-and-
whisker plots (Figure 3.1).  The plots were arranged such that, for each set of data, the values 
were organized into quartiles.  In these plots, each box contains the first to third quartile of the 
data, with the median indicated by a horizontal line inside the box.  Extending from the box, the 
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upper whisker is calculated as the third quartile plus 1.5 times interquartile range above the 
third quartile, and the lower whisker is calculated as the first quartile minus 1.5 times 
interquartile range below the first quartile, where the interquartile range is the difference 
between the third and first quartile.  Data points outside this range are considered as outliers 
and were indicated by dots above the upper whisker and below the lower whisker. 
 
	
 
Figure 3.1  How to interpret a box-and-whisker plot 
Box-and-whisker plots are arranged so that data is organized into quartiles.  Each box is 
enclosed by the upper and lower quartiles, with a horizontal line indicating the median of the 
data.  The interquartile range (IQR) spans from the first to the third quartile.  The upper whisker 
is the third quartile plus 1.5 times IQR above the third quartile, and the lower whisker is the 
first quartile minus 1.5 times IQR below the first quartile.  Additionally, the data above the 
upper whisker and below the lower whisker are outliers, represented as dots.   
 
 
3.3 Cell Lines 
3.3.1 Cell Lines and Culture Conditions 
MDA-MB-231 and BT-20 cells were purchased from the American Type Culture 
Collection (Manassas, VA, USA).  Cells were passaged for less than three months at a time 
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following resuscitations and therefore, no additional authentication was performed.  Both 
MDA-MB-231 and BT-20 monolayer cultures were maintained in the DMEM medium 
containing 10 % FBS (Gibco, Life Technologies), 1 % penicillin/streptomycin (Gibco, Life 
Technologies) and 1 mM sodium pyruvate (HyClone, GE Life Sciences,).   
 
3.3.2 Generation of Stable Cell Lines  
Stable MDA-MB-231 cell lines with restored EPHB6 expression were generated by 
transfecting MDA-MB-231 cells with the pcDNA3 expression vector encoding wild-type 
EPHB6 (MDA-B6) or Myc-tagged EPHB6 (MDA-B6-M).  Transfection with the empty vector 
was used as a control (MDA-pc3).  Stable EPHB6 knockdowns were generated using EPHB6-
targeting shRNA encoded in lentiviral particles (Santa Cruz Biotechnology, Dallas, TX, USA).  
Cells were transduced in the presence of 10 µg/mL polybrene (Sigma-Aldrich), followed by 5 
days of selection in the presence of 10 µg/mL puromycin (Sigma-Aldrich).  Transduction with 
SRC-targeting shRNA constructs and with green fluorescent protein (GFP)- or red fluorescent 
protein (RFP)-encoding cDNAs, required preparation of lentiviral particles.  
  
3.4 Generation of Lentiviral Particles 
Lentiviral particles were generated by transfection of HEK-293T cells, grown in 10 cm 
plates to ~70% confluence with psPAX2, pMD2.G, and with the lentiviral vector encoding the 
genes of interest.  Transfection took place in 10 mL of tissue culture medium with 1,400 µL 
Opti-Mem (Gibco, Life Technologies) and 93.6 µL X-treamGENE 9 DNA Transfection 
Reagent (Roche, Mississauga, ON, Canada).  Medium was changed after 18 hr and replaced 
with DMEM containing 2% w/v BSA and viral particles were collected 48 hr and 72 hr after 
transfection.  MDA-B6 and MDA-pc3 cells were transduced with the lentiviral particles by 
incubation overnight in medium containing 8 µg/mL polybrene.  The transduction medium was 
removed and transduced cells were incubated for 48 hr in cell culture medium containing 2 
µg/mL puromycin. 
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3.5 Pooled Screening Pipeline 
3.5.1 Determination of Multiplicity of Infection 
3 x 106 MDA-B6, MDA-B6-M, and MDA-pc3 cells were infected in duplicate with 0, 
0.031, 0.125, 0.5, 2, or 8 mL of the 90K lentiviral shRNA library in 15 cm tissue culture dishes.  
Cells were transduced in the presence of 8 µg/mL polybrene.  After 24 hr, media was removed 
and replaced with either medium containing 2 µg/mL puromycin or a control with medium 
alone for each viral volume.  Cells were incubated in puromycin-containing media or control 
media for 48 hr before being collected and counted.  The amount of living cells with each 
volume of virus was compared to the corresponding control in order to determine percentage of 
survival.  The percentage of survival, therefore, indicated the percentage of cells that were 
successfully transduced and acquired puromycin resistance.  The viral volume resulting in 30-
40 % survival indicates a multiplicity of infection (MOI) of 0.3-0.4 (Figure 3.2). 
 
 
 
Figure 3.2  Determination of viral volume needed for 0.3-0.4 MOI 
MDA-MB-231 cells were seeded in 15 cm plates with indicated volumes of lentiviral particles 
containing the 90K shRNA library, as well as 8 µg/mL of polybrene.  Cells were incubated in 
media containing 2 µg /mL puromycin and were counted after 48 hr and compared to 
puromycin-free controls.  Red lines indicate the range of viral volume that corresponds to a 0.3-
0.4 multiplicity of infection (MOI). 
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3.5.2 Transduction with 90K Library 
9 x 107 MDA-B6, MDA-B6-M, and MDA-pc3 cells were transduced with 90K lentiviral 
shRNAs from the RNAi Consortium lentiviral library (Sigma-Aldrich) in 15 cm tissue culture 
dishes at an MOI of 0.3-0.4.  Cells were transduced in the presence of 8 µg/mL polybrene.  
After 24 hr, media was removed and replaced with DMEM containing 2 µg/mL puromycin to 
eliminate uninfected cells.  Cells were incubated in the presence of puromycin for 48 hr before 
being collected and divided into 3 replicates of 1.8 x 107 cells per cell line.  This was time point 
0 (T0) of the screen, and in addition, 3 tubes of 2 x 107 cells from each cell line were pelleted 
and frozen for T0 genomic DNA.  
 
3.5.3 Outgrowth Assay 
After T0 of the screen, individual replicates of MDA-B6, MDA-B6-M, and MDA-pc3 
were passaged separately.  1.8 x 107 cells of each replicate were passaged to fresh plates upon 
reaching ~80% confluency.  As with T0, 3 tubes of 2 x 107 cells from each replicate were 
pelleted and frozen for genomic DNA extraction.  Cells were kept in DMEM containing 2 
µg/mL puromycin throughout the outgrowth assay.  The assay was terminated 17 days after the 
initial puromycin selection (T17). 
 
3.5.4 Genomic DNA Extraction and Processing 
Frozen cell pellets from the pooled screen were thawed, resuspended in 4.5 mL PBS, and 
vortexed thoroughly.  Genomic DNA was then extracted from the cell suspensions using the 
QIAamp DNA Blood Maxi Kit (Qiagen, Toronto, ON, Canada), according to the 
manufacturer’s instructions.  Following elution in buffer AE (Qiagen), the eluted DNA solution 
was made up to 500 µL with addition of water.  20 µL of 5 M NaCl (Sigma) was added to the 
DNA, followed by 1 mL of -20 °C 96 % ethanol.  Tubes were mixed by inversion, and 
centrifuged for 15 min at 15,000 xg and 4 °C.  The supernatant was aspirated and the DNA 
pellet was washed by the addition of 500 µL of -20 °C 70 % ethanol and subsequent inversion.  
Tubes were centrifuged for 10 min at 15,000 xg and 4 °C, followed by aspiration of the 
supernatant and air-drying for 5 min.  DNA pellets were resuspended in 10 mM Tris-HCl pH 
7.5 for a final concentration of 400 ng/µL and heated for 1 hr at 50 °C.  Extracted genomic 
DNA was stored at -20 °C until the probe preparation. 
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3.5.5 Probe Preparation 
Genomic DNA was amplified by large-scale PCR.  A master mixture was prepared for 
each sample containing 28 µg of template DNA, 2x PCR buffer, 2x enhancer solution, 300 µM 
of each dNTP, 900 µM of each oligonucleotide primer (PCR_BF 5'- Biotin-
AATGGACTATCATATGCTTACCGTAACTTGAA-3' and PCR_R 5'- 
TGTGGATGAATACTGCCATTTGTCTCGAGGTC-3') (Sigma), 50 mM MgSO4, 18 µL of 
Platinum Pfx polymerase (Invitrogen), and water up to 1,200 µL.  The master mix was divided 
into 50 µL aliquots for PCR.  The amplification PCR reaction was carried out by denaturing 
once at 98 °C for 3 min, followed by (98 °C for 10 sec, 55 °C for 15 sec, 72 °C for 15 sec) x29, 
72 °C for 5 min, then cooling to 4 °C.  A test sample of PCR product (178 bp) was run on a 2% 
agarose gel to ensure that amplified shRNAs did not form into cruciform structures (225 bp).  
The PCR products were then purified using the QIAquick PCR Purification Kit (Qiagen) 
according to the manufacturer’s instructions.  Purification was done immediately to avoid 
conversion of linear shRNAs to cruciform structures.  Amplification products were purified and 
digested with XhoI (New England Biolabs, Whitby, ON, Canada).  120 µL of PCR product was 
mixed with 10x NEB Buffer 2 (New England Biolabs) and 100x BSA.  The digestion reaction 
was carried out at 37 °C for 2 hr, followed by 65 °C for 20 min, then cooling to 4 °C.  The 
digested product was then gel purified using low-melting agarose and remaining salts were 
removed using a PCR Purification Kit (Qiagen).  The final product was eluted in two 30 µL 
volumes of EB Buffer (Qiagen), with an average yield of 4 to 6 µg of purified sample. 
 
3.5.6 Microarray Hybridization 
Hybridization of the stable half-hairpins was carried out on UT-GMAP 1.0 microarrays 
(Affymetrix Inc, Santa Clara, CA, USA).  After warming to room temperature, microarrays 
were preconditioned by filling with Pre-Hybridization Mix from the GeneChip Hybridization, 
Wash, and Stain kit (Affymetrix) and incubation in a hybridization oven at 40 °C for 30 min at 
60 rpm.  A hybridization mixture was prepared for each sample containing 66 µL of 2x 
hybridization buffer (Sigma), 1.32 µL of 50 mg/mL BSA, 1.32 µL of 10 mg/mL herring sperm 
DNA (Invitrogen), 1.3 µL of 5 nM B213 (Sigma), 1.38 µL of spike-in controls (Sigma), 25 µL 
of 20 µM blocking oligo mixture (Sigma), and 13.2 µL DMSO.  To the hybridization mix was 
added 28.5 µL containing water and 2 µg of purified probe sample.  The hybridization mix was 
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incubated at 99 °C for 10 min, followed by incubation at 40 °C for 5 min, and then centrifuged 
at 15,000 xg for 5 min.  The hybridization mix was then added to the preconditioned microarray 
and the microarray was incubated in the hybridization oven at 40 °C for 24 hr at 60 rpm. 
 
 
3.5.7 Microarray Washing 
Mashing of the hybridized microarrays was carried out using Stain Cocktails 1 and 2 from 
the GeneChip Hybridization, Wash, and Stain kit (Affymetrix).  Prior to washing, hybridization 
mix was removed from microarrays and stored at -20 °C, and microarrays were filled with wash 
buffer A.  Microarray washing was carried out in a GeneChip Fluidics Station 450 (Affymetrix) 
according to the manufacturer’s instructions using the FlexFS450_0001 protocol. 
 
3.5.8 Microarray Scanning  
Microarray scanning was carried out using a GeneChip Scanner 3000 (Affymetrix).  The 
generated .CEL files were read using the Saskatchewan Cancer Agency differential essentiality 
mapping system (SCADEMS) in order to determine individual shRNA probe intensities. 
 
3.6 Computational Analysis of Screen Results 
For each hairpin, the signal intensity was normalized and converted to log2 scale for each 
time point of both MDA-wild type, and MDA-pc3 samples.  Note that the MDA-wild type 
samples were either MDA-B6 or MDA-B6-M.  Hairpins whose signal was below the 
background (i.e. log2 scale of less than 8) at time point T0 were discarded.  Likewise, hairpins 
with fold-change greater than or equal to 1.25 at a time point relative to the corresponding 
previous time point were also discarded.  For each replicate, the difference of cumulative 
change (DCC) between the MDA-pc3 and MDA-wild type conditions were calculated for time 
points relative to the corresponding previous time point using the formula: 
𝐷𝐶𝐶 =  (𝑥!,!!"!!!!! − 𝑥!!!,!!"! )−  (𝑥!,!!!!!! − 𝑥!!!,!! )	
where 𝑥!,!!"!  is the normalized signal intensity at time point 𝑡 ∈ (0, . . ,𝑇) and for replicate 𝑘 ∈ (1, . . ,𝐾) for MDA-pc3 samples.  Likewise, 𝑥!,!!  represent the same for MDA-B6 or MDA-
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B6-M samples.  The DCC fitness score was then calculated for each gene by taking the two 
hairpin DCC values that were the most negative values for that gene.   𝐷𝐶𝐶! = 𝑎𝑟𝑔min!,!" [𝐷𝐶𝐶!,! +  𝐷𝐶𝐶!,!"] /2	
Next, the permutation test was performed by randomly shuffling the DCC scores.  This process 
was repeated and an empirical distribution of the DCC fitness scores over all of the genes was 
constructed.  Finally, significant p-values for each observed fitness score were estimated as the 
frequency of randomized, shuffled DCC with more negative scores.  
𝑝 =  1𝑁𝐿  𝐼(𝐷𝐶𝐶! <!"!!!  𝐷𝐶𝐶!)	
where N is the number of genes, L is the number of repeats done to construct an empirical 
distribution, 𝐷𝐶𝐶! is the randomized shuffle with more negative score, and 𝐼( ) is a binary 
indicator that gives 1 for a true statement, and 0 otherwise. 
 
3.7 CRISPR/Cas9 Analysis and Validation 
MDA-B6 and MDA-pc3 cells were seeded in 6-well plates and transduced with src-
targeting sgRNA lentiviral constructs that also encoded BFP, from MilliporeSigma/welcome 
trust Sanger (Sigma-Aldrich), in the presence of 8 µg/mL of polybrene.  Following 48 hr of 
selection with 2 µg/mL puromycin, selected cells were seeded in 96-well optical bottom plates 
(ThermoFisher Scientific), allowed to adhere for 24 hr, and transfected with CMV-Cas9-2A-
GFP (Sigma) using the Lipofectamine LTX and Plus Reagent kit (ThermoFisher Scientific) 
according to the manufacturer’s instructions.  Cells were imaged every 24 hr for six days after 
transfection using the ImageXpress Micro XLS widefield automated fluorescence microscope 
(Molecular Devices, Sunnyvale, CA, USA) to capture BFP and GFP signals.  Cells expressing 
BFP or co-expressing BFP and Cas9-GFP were quantified using MetaXpress version 6 
(Molecular Devices).  src knockout was confirmed using the GeneArt Genomic Cleavage 
Detection kit (ThermosFisher Scientific) according to the manufacturer’s instructions. 
 
3.8 Drug Sensitivity Assays 
3.8.1 Drug Sensitivity for Individual Cell Lines 
MDA-MB-231 and BT-20 cell monolayers were incubated in 96-well plates for 72 hr and 
96 hr, respectively, in the presence of indicated concentrations of SU6656 or KX2-391, or 
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matching volumes of DMSO as a solvent control.  Treated cells were stained using resazurin by 
following the manufacturer’s instructions and fluorescence was measured using a SpectraMax 
M5 microplate reader. 
 
3.8.2 Drug Sensitivity for Mixed Fluorescent Cell Lines 
For color assays, MDA-B6 and MDA-pc3 cells were transduced with pLD-GFP-Puro and 
pLD-RFP-Puro (Previsouly described in Vizeacoumar et al., 2013) in lentiviral vectors, in 
medium containing 8 µg/mL polybrene.  After 48 hr, transduced cells were selected in the 
presence of 2 µg/mL puromycin to produce stable cell lines.  MDA-B6-GFP and MDA-pc3-
RFP, or MDA-B6-RFP and MDA-pc3-GFP cells were co-seeded in equal numbers in 12-well 
plates at indicated cell densities.  Seeded cells were incubated for 72 hr in the presence of 25 
nM KX2-391 or a matching volume of DMSO.  Treated cells were collected and quantitated by 
flow cytometry.  Results were analyzed using the FlowJo software (FLOWJO LLC, Ashland, 
OR, USA). 
 
3.9 Immunoprecipitation and Western Blotting 
Cells were rinsed with ice-cold PBS and lysed using lysis buffer containing 0.1 M EDTA, 
0.3 M Tris, 0.1 M NaCl, 6 mM PMSF, and 3 mM sodium ortho-vanadate.  Cell debris was 
removed by centrifugation.  For immunoprecipitation, 2-3 µg of required antibody, with 25 µL 
of protein G Sepharose beads (GE Healthcare Life Sciences, Baie d’Urfe, QB, Canada) were 
added.  Samples were rotated at 4 °C overnight and beads were washed three times with lysis 
buffer.  Cell lysates or immunoprecipitates were resolved using SDS-PAGE, followed by 
transfer to nitrocellulose membranes (Amersham, GE Healthcare Life Sciences).  Membranes 
were blocked with 5 % non-fat dry milk in 0.1 % PBS/Tween-20, or with 5 % BSA in 
TBS/Tween-20 and incubated overnight with primary antibodies at 4 °C.  At this stage, 
membranes were rinsed 3 times with PBS or TBS, incubated for 1 hr with fluorescently labeled 
secondary antibodies (LI-COR Biotechnology, Guelph, ON, Canada), and protein images were 
acquired using the LI-COR Odyssey imaging system (LI-COR Biotechnology).  Figures were 
generated using the Odyssey, Carestream, and PowerPoint software.  Cropping of Western blot 
images was done with PowerPoint.  Brightness and contrast were adjusted in Western blot 
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images using Carestream and PowerPoint software to optimize image presentation.  Western 
blotting with anti-tubulin was used as a loading control. 
 
3.10 Cell Death Assays 
3.10.1 Propidium Iodide Staining 
For PI staining, MDA-MB-231 and BT-20 cells were incubated in glass-bottom plates 
(MatTek, Ashland, MA, USA) for 72 hr and 96 hr, respectively, in the presence of 25 nM and 
35 nM KX2-391, respectively, and matching volumes of DMSO.  Cells were then incubated in 
the presence of 2.7 µg/ml PI for 12 minutes and washed with phenol red-free medium.  The 
amount of PI-stained cells was analyzed by microscopy using a Zeiss Observer Z1 at 200 x 
magnification.  Brightness of presented confocal microscopy images was adjusted using the 
Zen 2012 Software (version 8.0) to optimize the visualization of PI staining.  PI-stained cells 
were counted in at least 10 randomly captured frames, normalized on the total number of cells 
in matching frames, and compared between DMSO controls and treated cells. 
 
3.10.2 7-AAD Staining 
For 7-AAD staining, MDA-MB-231 and BT-20 cells were incubated in 6-well plates for 
72 hr and 96 hr, respectively, in the presence of 25 nM KX2-391 and matching volumes of 
DMSO.  Cells were collected and stained with 7-AAD according to the manufacturer’s 
instructions, prior to flow cytometry analysis.  Results were analyzed using the FlowJo software 
(FLOWJO LLC). 
 
3.11 Tumor Xenograft Studies 
3.11.1 Mouse Models 
Breeder pairs of NOD SCID gamma mice were purchased from The Jackson Laboratory 
and a colony was established at the Laboratory Animal Services Unit, University of 
Saskatchewan.  Mice were housed in sterile cages and maintained in pathogen-free aseptic 
rooms, while being fed autoclaved food pellets and water ad libitum.  All animal protocols were 
reviewed and approved by the University of Saskatchewan Animal Research Ethics Board.  
Xenograft tumors were established by injection of 1x106 MDA-B6 or MDA-pc3 in 100 µL PBS 
into the mammary fat pads of 4-6 week old female animals.  Treatment with KX2-391 was 
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initiated when tumors became palpable.  Mice were fed with either KX2-391 in DMSO (5 
mg/kg) or a matching volume of DMSO diluted with ultra-pure water.  Treatments were 
administered orally twice per day for at least 20 days.  Digital caliper measurements were taken 
every 3 days and tumor volume was calculated by the formula A/2*B2 (where A and B were the 
long and short diameters of the tumor respectively).  At the end of the experiments animals 
were sacrificed and tumors were removed.  Tumors were fixed in 10% buffered formalin for 
paraffin embedding. 
 
3.11.2 Immunohistochemistry 
For the immunohistochemical staining, tumors were dissected and fixed in 10% neutral- 
buffered formalin for 24-48 hr.  The tumors were paraffin embedded, sectioned to 4 µm 
thickness, and affixed on a slide.  Simultaneous dewaxing and antigen retrieval was performed 
on the Dako PT Link using Target Retrieval Solution-High pH (Dako Canada, Burlington, ON, 
Canada).  Staining was performed on the Dako Autostainer Link using anti-CD34 (Abcam, 
Toronto, ON, Canada) antibody and the Dako FLEX DAB+Detection Kit.  In each stained 
tumor section, 12, 3, 6 and 9 o’clock fields were imaged at 100 x magnification and the density 
of stained blood vessels per field was quantified using the Image-Pro Premier software. 
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4.0 Results 
4.1 Expression Analysis 
A systematic analysis of the gene expression data from The Cancer Genome Atlas 
(TCGA) dataset (https://tcga-data.nci.nih.gov/tcga/) was carried out in the Freywald lab by 
Frederick Vizeacoumar.  The data provided by TCGA showed mRNA expression levels, which 
had been analyzed using RNA Seq V2 and was normalized using the RSEM normalization.  
This analysis confirmed that EPHB6 is indeed downregulated in many malignancies (Figure 
4.1).  Therefore, if targetable synthetic lethal partners could be determined for EPHB6, then the 
therapeutic results would be potentially applicable to a wide array of cancer types.  
Additionally, it has previously been suggested that transcriptional regulation of EPHB6 is 
controlled by promoter methylation in breast cancer cell lines (Fox and Kandpal, 2006).  
Therefore, cancer methylome data for multiple malignancies was obtained from TCGA and 
analyzed in the Freywald lab by Frederick Vizeacoumar.  For each cancer type, one ephB6 
methylation site was selected that most negatively correlated with EPHB6 expression.  This 
methylation site was then compared between normal and tumor tissues.  In this analysis, it was 
found that EPHB6 is methylated in the promoter region in a number of different malignancies, 
including breast, colon, lung, and prostate tumors, relative to normal tissue (Figure 4.2). 
Assessment of TCGA data for immunohistochemistry-based breast cancer subtype 
classification, carried out in the Freywald lab by Frederick Vizeacoumar, revealed that EPHB6 
is also significantly downregulated in patient samples, representing very heterogeneous and 
aggressive tumors of the TNBC group (Figure 4.3).  The data provided by TCGA showed 
mRNA expression, which had been analyzed using RNA Seq V2 and was normalized using the 
RSEM normalization.  Computational analysis confirmed that 37% of TNBC samples showed a 
two-fold lower expression of EPHB6 when compared to expression in normal tissue samples. 
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Figure 4.1  EPHB6 expression is downregulated in many malignancies 
A box-and-whisker plot showing EPHB6 expression data for different cancer types and 
matching normal tissue controls provided by The Cancer Genome Atlas (TCGA).  The data 
provided by TCGA showed mRNA expression levels, which had been analyzed using RNA Seq 
V2 and was normalized using the RSEM normalization according to TCGA standards.  The 
number of samples analyzed is shown on the x-axis.  Statistical significance was computed 
using the Mann-Whitney U test.  A full description of box-and-whisker plot interpretation is 
included in the Materials and Methods. 
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Figure 4.2  The ephb6 promoter is methylated in multiple malignancies 
A box-and-whisker plot showing ephb6 methylation data for different cancer types and 
matching normal tissue controls provided by The Cancer Genome Atlas (TCGA).  For each 
cancer type, one ephB6 methylation site was selected that most negatively correlated with 
EPHB6 expression.  This methylation site was then compared between normal and tumor 
tissues.  The number of samples analyzed is shown on the x-axis.  A full description of box-
and-whisker plot interpretation is included in the Materials and Methods. 
 
 
Normal 
Tumor 
Bladder urothelial carcinoma 
Breast invasive carcinoma 
Cervical squamous cell carcinoma 
Colon adenocarcinoma 
Head and neck squamous cell carcinoma 
Kidney renal clear cell carcinoma 
Kidney renal papillary cell carcinoma 
Liver hepatocellular carcinoma 
Lung adenocarcinoma 
Lung squamous cell carcinoma 
Pancreatic adenocarcinoma 
Prostate adenocarcinoma 
Rectum adenocarcinoma 
Sarcoma 
Skin cutaneous melanoma 
Stomach adenocarcinoma 
Thyroid carcinoma 
Uterine corpus endometrial carcinoma 
N 
T 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
0.0 
EPHB6 methylation 
N.S. 
<0.01 <0.01 
N.S. <0.05 N.S. 
<0.01 N.S. 
<0.01 
<0.01 N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
<0.01 
<0.01 
<0.01 
N
 2
1 
T 
25
3 
N
 9
2 
T 
73
5 
N
 3
 
T 
21
1 
N
 3
8 
T 
27
4 
N
 5
0 
T 
51
6 
N
 1
60
 
T 
29
5 
N
 4
5 
T 
18
2 
N
 4
9 
T 
20
4 
N
 2
9 
T 
43
5 
N
 4
1 
T 
36
1 
N
 9
 
T 
91
 
N
 4
9 
T 
33
6 
N
 7
 
T 
95
 
N
 4
 
T 
17
0 
N
 2
 
T 
37
4 
N
 2
 
T 
32
6 
N
 5
6 
T 
50
0 
N
 3
3 
T 
41
6 
M
et
hy
la
tio
n 
(H
M
45
0)
 
	 30	
 
Figure 4.3  EPHB6 expression in normal and TNBC samples 
A box-and-whisker plot showing EPHB6 expression data for triple negative breast cancer 
(TNBC) and matching normal tissue controls provided by The Cancer Genome Atlas (TCGA).  
The data provided by TCGA showed mRNA expression, which had been analyzed using RNA 
Seq V2 and was normalized using the RSEM normalization according to TCGA standards.  The 
number of samples analyzed is shown on the x-axis.  Statistical significance was computed 
using the Mann-Whitney U test.  A full description of box-and-whisker plot interpretation is 
included in the Materials and Methods. 
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tagged EPHB6 (MDA-B6-M).  In addition, MDA-MB-231 cells were transfected with the 
empty pcDNA3 vector for use as a control (MDA-pc3) (Figure 4.4).  These cells were 
described in previous work by the Freywald lab (Truitt et al., 2010).  In addition, appropriate 
expression of the EPHB6 receptor on the surface of MDA-B6 and MDA-B6-M cells was 
confirmed by flow cytometry (Figure 4.5). 
 
 
Figure 4.4  EPHB6 expression in MDA-MB-231 cells lines 
EPHB6 expression is shown in EPHB6-deficient triple negative MDA-MB-231 breast cancer 
cells stably transfected with the pcDNA3 expression vector encoding EPHB6 (MDA-B6), myc-
tagged EPHB6 (MDA-B6-M), or mock-transfected with empty pcDNA3 (MDA-pc3).  
Expression of EPHB6 was examined by Western blotting with anti-EPHB6 antibody.  Western 
blotting with anti-tubulin was used as a loading control. 
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Figure 4.5  EPHB6 expression on MDA-MB-231 cell surfaces 
To observe expression of EPHB6 on cell surfaces, MDA-pc3, MDA-B6, and MDA-B6-M cells 
were stained with anti-EPHB6 and a FITC-conjugated secondary antibody, and analyzed by 
flow cytometry and the FlowJo software.  Matching non-specific IgG was used as a control 
(Control IgG). 
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After the microarrays were scanned, it was necessary to assess the correlation between the 
replicates from each cell line and time point.  It was expected that there would be at least some 
difference between the replicates, not least of all due to the differential SL effects in the MDA-
pc3 populations relative to the EPHB6-expressing cell lines.  However, genetic interactions are 
not common (Boone et al., 2007), meaning that a high degree of similarity between the various 
replicates would be anticipated.  A Pearson analysis measures the linear correlation between 
two sets of data, and was performed between each of the replicates from the pooled screen, 
from each cell line and time point.  The data was represented as a correlation clustergram, 
wherein the density plots of the three screens (MDA-B6, MDA-B6-M, and MDA-pc3) showed 
a great deal of similarity among the replicates (Figure 4.6).  This ensured high reproducibility, 
thereby permitting further analysis of the data. 
 
 
Figure 4.6  Clustergram showing Pearson correlation for EPHB6 screens 
Pearson analysis showing linear correlation between replicates of the EPHB6 synthetic lethal 
pooled screen.  Each cell line and time point is clustered using hierarchical clustering with 
complete linkage.  The time points are T0, T10, or T17, representing days after the start of the 
experiment.  The replicates of each cell line are represented as Rep1 or Rep2. 
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Because genetic interactions are rare (Boone et al., 2007), it was important that the 
different replicates all displayed a relatively high correlation, which was even observable at the 
different time points.  This confirmed that a few highly sensitive SL interactions were detected 
in the screens, in both the MDA-B6 and MDA-B6-M cell lines.  Once a fitness score was 
determined for all genes from the MDA-B6, MDA-B6-M, and MDA-pc3 screens, these values 
were compared to known sets of essential and non-essential genes.  A recent framework was 
developed for evaluating the quality of genome-scale lethality screens through the assembly of 
reference sets of both essential and non-essential genes, while providing a Bayesian classifier of 
gene essentiality (Hart et al., 2014).  Such an analysis utilizes both precision and recall, where 
precision indicates how accurate a screen is in determining essential genes, while recall 
indicates how many of the total known essential genes were identified by the screen.  Precision 
and recall are then combined for a value known as the F-measure, meaning that F-measure 
correlates directly with the screen performance.  Using this measuring stick, it was found that 
all three screens recorded excellent performance scores, with F-measures of >0.7 (Figure 4.7). 
 
 
Figure 4.7  Precision recall curve showing performance of EPHB6 screens 
Precision (accuracy compared to known essential genes) recall (amount of known essential 
genes identified by the screen) curve measuring the core essential and non-essential genes 
identified by the EPHB6 pooled screen against a known set of essential genes.  F-measures 
combine precision and recall, with an F-measure of > 0.7 indicating a high performance. 
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The trend of the hairpins that dropped out specifically in EPHB6-deficient cells at 
different time points was computed as the Difference of Cumulative Change (DCC) score to 
identify top hits.  Essentially, the DCC score represents the comparison between the EPHB6-
expressing and the EPHB6-deficient cells, with a lower score denoting a lower relative fitness 
in the EPHB6-deficient cells for a given gene.  In calculation of the DCC score, the use of the 
top two hairpin scores per gene increased the confidence of the SL hits and allowed avoidance 
of possible off-target effects.  Both myc-tagged (MDA-B6-M) and untagged (MDA-B6) 
versions of EPHB6 in EPHB6-positive cells were used for comparison against EPHB6-deficient 
MDA-pc3.  Therefore, the DCC scores from both screens (MDA-B6-M vs. MDA-pc3 and 
MDA-B6 vs. MDA-pc3) were compared, and the overlap was used to identify 113 statistically 
significant overlapping hits (P < 0.05) (Figure 4.8) (Table 4.1).  This approach identified a 
number of potential therapeutic candidates that predominantly functioned in cell signaling 
pathways (Figure 4.9), including molecules such as DDR2, SRC, ROCK, and MET. 
 
 
 
Figure 4.8  Overlapping significant hits from both EPHB6-positive screens 
Scatter plot showing the difference of cumulative change (DCC) score for every gene when 
MDA-pc3 is compared to both MDA-B6 and MDA-B6-M.  A low DCC score for a given gene 
means that when that gene is inactivated, there is a loss of fitness in the EPHB6-deficient cells, 
but not in the EPHB6-expressing cells.  Alternatively, a high DCC score means the fitness of 
EPHB6-deficent cells is high relative to that of EPHB6-expressing cells when the given gene is 
inactivated. 
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Table 4.1  Significant EPHB6 synthetic lethal hits 
Gene ID Gene Symbol Gene ID Gene Symbol Gene ID Gene Symbol 
22848 AAK1 51575 ESF1 5188 PET112L 
84680 ACCS 54932 EXD3 9867 PJA2 
2182 ACSL4 84668 FAM126A 5315 PKM2 
348158 ACSM2B 220965 FAM13C 5334 PLCL1 
202 AIM1 2091 FBL 10631 POSTN 
23780 APOL2 2210 FCGR1B 5636 PRPSAP2 
55156 ARMC1 2260 FGFR1 167681 PRSS35 
405 ARNT 2574 GAGE2C 51195 RAPGEFL1 
570 BAAT 2632 GBE1 9584 RBM39 
28984 C13orf15 81025 GJA9 5979 RET 
56260 C8orf44 65056 GPBP1 9475 ROCK2 
56934 CA10 3001 GZMA 6235 RPS29 
1233 CCR4 3601 IL15RA 122042 RXFP2 
925 CD8A 54756 IL17RD 55176 SEC61A2 
997 CDC34 3656 IRAK2 5268 SERPINB5 
28316 CDH20 23281 KIAA0774 219855 SLC37A2 
1044 CDX1 57542 KLHDC5 254428 SLC41A1 
64781 CERK 342574 KRT27 6533 SLC6A6 
254263 CNIH2 84456 L3MBTL3 162394 SLFN5 
1355 COX15 64175 LEPRE1 4184 SMCP 
1348 COX7AP2 4294 MAP3K10 23049 SMG1 
151835 CPNE9 23101 MCF2L2 57154 SMURF1 
1441 CSF3R 1954 MEGF8 8303 SNN 
168002 DACT2 4233 MET 11166 SOX21 
4921 DDR2 79083 MLPH 6659 SOX4 
8694 DGAT1 93380 MMGT1 6709 SPTAN1 
55567 DNAH3 51373 MRPS17 6714 SRC 
4189 DNAJB9 51649 MRPS23 30968 STOML2 
1776 DNASE1L3 4693 NDP 374618 TEX9 
1801 DPH1 4722 NDUFS3 55706 TMEM48 
1781 DYNC1I2 4763 NF1 7132 TNFRSF1A 
8798 DYRK4 28511 NKIRAS2 7166 TPH1 
1909 EDNRA 93034 NT5C1B 22974 TPX2 
30846 EHD2 10204 NUTF2 80128 TRIM46 
84285 EIF1AD 57489 ODF2L 25989 ULK3 
2020 EN2 56288 PARD3 8975 USP13 
2036 EPB41L1 64081 PBLD 23174 ZCCHC14 
29924 EPN1 27043 PELP1 	 	
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Figure 4.9  Known Gene Ontology terms for EPHB6 significant hits 
Analysis showing Gene Ontology Consortium (geneontology.org) terms associated with each 
significant hit in the EPHB6 synthetic lethal screen.  Genes are assigned specific Gene 
Ontology terms based on a combination of the molecular function, cellular component, and 
biological process associated with that gene. 
 
 
In addition to analysis using Gene Ontology terms, further analysis was carried out for of 
the 113 significant hits using the Compartments Subcellular Localization Database (CSLD) 
(compartments.jensenlab.org).  The CSLD provides information on the most probable cellular 
locations of expressed gene products based on past research.  Consistent with the receptor 
functions of EPHB6, and its inherent cell membrane affiliation, cellular analysis with CSLD 
revealed that several of the functional products of significant gene hits also spatially associated 
with the cell surface (Figure 4.10).  This was interesting to note, as genetic interactions are rare 
(Boone et al., 2007), and so it would be expected, though not necessarily required, that at least 
some of the negative genetic interactions with EPHB6 would also be found associated with the 
same cellular region.  In fact, more than 30 % of the 113 significant hits had a high likelihood 
of expression either at the cellular membrane, or in the extracellular space. 
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Figure 4.10  Expected cellular locations of significant hits 
Expected cellular distribution of each significant hit from the EPHB6 synthetic lethal screen 
according to information from the Compartments Subcellular Localization Database 
(compartments.jensenlab.org).  The database identifies protein cellular distribution based on 
literature, high-throughput screens, automatic text mining, and sequence-based predictions. 
 
 
4.3 Identification and Validation of SRC as a Therapeutic Target 
The next step was to prioritize a potential target for further validation from the EPHB6 
SL screen. To systematically identify potential candidates for further investigation, a novel 
approach was utilized, whereby SL data was coupled with gene expression profiling.  It seemed 
rational that increased expression of a SL gene in EPHB6-deficient cells would most likely 
represent an essential compensatory mechanism.  In order to identify such essential molecules, 
the correlation between EPHB6 expression and that of each SL hit was compiled and analyzed.  
Membrane / extracellular 
37 (32.7%) 
Unknown 
4 (3.6%) 
Cytoskeleton 
7 (6.2%) 
Golgi apparatus 
4 (3.6%) 
Cytoplasm 
21 (18.6%) 
Endoplasmic reticulum 
5 (4.4%) 
Nucleus 
24 (21.2%) 
Lysosome 
1 (0.9%) 
Mitochondria 
10 (8.8%) 
	 39	
This analysis was carried out across 25 different tumor types and specifically searched for a 
negative correlation between expression of EPHB6 and a SL gene.  Remarkably, it was found 
that the non-receptor tyrosine kinase, SRC, was clustered with a set of genes that mostly 
correlated negatively with EPHB6 expression (Figure 4.11).  Consistent with this finding, 
TCGA data, analyzed in the Freywald lab by Frederick Vizeacoumar, showed that SRC is 
overexpressed in multiple malignancies (Figure 4.12). 
 
Figure 4.11  SRC clusters with genes negatively correlated with EPHB6 expression 
Correlation clustergram showing the expression of significant synthetic lethal hits (vertical) 
from the EPHB6 screen, relative to EPHB6 expression in various cancer types (horizontal).  
Negative expression correlations are blue and positive correlations are red.  Expression data 
was provided by The Cancer Genome Atlas (TCGA).  The data provided by TCGA showed 
mRNA expression levels, which had been analyzed using RNA Seq V2 and was normalized 
using the RSEM normalization.  
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Figure 4.12  SRC is overexpressed in many malignancies 
A box-and-whisker plot showing SRC expression data for different cancer types and matching 
normal tissue controls provided by The Cancer Genome Atlas (TCGA).  The data provided by 
TCGA showed mRNA expression levels, which had been analyzed using RNA Seq V2 and was 
normalized using the RSEM normalization according to TCGA standards.  The number of 
samples analyzed is shown on the x-axis.  Statistical significance was computed using the 
Mann-Whitney U test.  A full description of box-and-whisker plot interpretation is included in 
the Materials and Methods. 
 
 
Not only is SRC often overexpressed in multiple malignancies, but it is also highly 
connected to many of the other hits obtained from the screen.  A functional network analysis of 
all of the 113 hits was carried out using the STRING 10 database (http://string-db.org), which 
quantitatively integrates genomic and previously established interactions.  This analysis 
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positioned SRC as a hub with high connectivity to the rest of the hits (Figure 4.13). 
 
 
 
Figure 4.13  STRING 10 analysis of EPHB6 synthetic lethal hits 
Network generated from the STRING 10 database (http://string-db.org) based on known 
interactions of the 113 significant hits from the EPHB6 synthetic lethal screen.  The interactions 
include both direct (physical) and indirect (functional) associations.  Each interaction stems 
from computational predictions, from knowledge transfer between organisms, and from 
interactions aggregated from other databases. 
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SRC was identified as a significant SL hit associated with EPHB6 deficiency (Table 4.1).  
It was also shown to be negatively correlated with EPHB6 expression (Figure 4.11), suggesting 
that it plays some compensatory role, which was validated by the observation that SRC is 
overexpressed in a number of different malignancies (Figure 4.12).  Lastly, SRC is shown to 
have a high connectivity to many of the other 113 SL hits from the EPHB6 screen.  Overall, 
these observations identified SRC as a molecule of choice for targeting EPHB6-deficient breast 
cancer cells.  Therefore, to validate the SL properties of SRC in EPHB6-deficient cells, an 
individual hairpin that efficiently silenced SRC expression was used in the MDA-B6 and 
MDA-pc3 cell lines (Figure 4.14A).  In agreement with the SL screen, it was found that 
silencing of SRC with this hairpin caused a preferential suppression of EPHB6-deficient MDA-
pc3 cells (Figure 4.14B). 
 
 
Figure 4.14  Validation of synthetic lethality with a SRC-targeting hairpin 
A) SRC expression after MDA-pc3 and MDA-B6 cells were transduced with SRC-targeting 
shRNA (sh149), or non-silencing shLuciferase (shLuc).  SRC expression was analyzed by 
Western blotting with anti-SRC.  Western blotting with anti-tubulin was used as a loading 
control.  B) MDA-pc3 and MDA-B6 cells were transduced with SRC-targeting shRNA and 
cultured for 96 hr after puromycin selection.  Cells were stained with resazurin and 
fluorescence was measured using a SpectraMax M5 microplate reader to determine cell 
suppression.  The experiment was performed at least three times. *, P < 0.05. 
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To completely exclude the involvement of potential off-target effects of shRNA 
molecules, a further validation of the SL relationship between EPHB6 and SRC was carried out 
using the CRISPR/Cas9-based system (Figure 4.15).  CRISPR/Cas9 utilizes single guide RNAs 
(sgRNA), which direct Cas9 to the gene of interest for cleavage.  Because Cas9 only cuts the 
individual gene of interest, this allows for effective knockout, with little off-target effect.  To 
this end, MDA-B6 and MDA-pc3 cells were transduced with a construct containing an sgRNA 
targeting src.  The stably transduced cells were then transfected with Cas9, thereby initiating 
knockout of src, and were imaged over a period of six days (Figure 4.16).  Consistent with the 
earlier observations based on SRC-silencing shRNAs, knockout of src with the CRISPR/Cas9 
approach mostly affected EPHB6-defficient MDA-pc3 cells and produced only a limited effect 
on MDA-B6, thus further confirming the SL interaction between EPHB6 and SRC (Figure 
4.17A).  The preferential negative effect on MDA-pc3 cell survival, compared to MDA-B6 
cells, was additionally confirmed through determination that both MDA-B6 and MDA-pc3 
were both transfected with Cas9 with a similar efficiency (Figure 4.17B).  Efficiency of 
cleavage of src by Cas9 was confirmed using the GeneArt Genomic Cleavage Detection kit 
(Figure 4.18). 
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Figure 4.15  Outline of the CRISPR/Cas9 method used for cleavage of src 
A) A sgRNA-encoding plasmid is inserted into the cell via a lentiviral vector and is directed to 
the genome where it is integrated.  The encoded sgRNA then forms a complex with a cellular 
apoptosis susceptibility (Cas) protein.  In this scenario, Cas is inserted into the cell via transient 
transfection.  Once the complex is formed, the sgRNA directs Cas to the target gene where Cas 
mediates a double strand break and knockdown of the gene at the genomic level.  B) Schematic 
representation of the CRISPR/Cas9 strategy to validate the SL interaction.  Cells of interest are 
stably transduced with a construct encoding src-targeting sgRNA and blue fluorescent protein 
(BFP), followed by the selection in the presence of 2 µg/mL of puromycin.  The selected cells 
are transiently transfected with a construct encoding Cas9-2A-GFP. 
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Figure 4.16  Images of MDA-B6 and MDA-pc3 cells following Cas9 transfection 
MDA-pc3 and MDA-B6 cells were stably transduced with a src-targeting sgRNA construct that 
also encoded the blue fluorescent protein (BFP) and selected in the presence of 2 µg/ml of 
puromycin.  The selected cells were transiently transfected with Cas9-GFP in 96-well plates.  
Green and blue fluorescence was quantified using the ImageXpress Micro XLS widefield 
automated fluorescence microscope and the MetaXpress version 6 software.  The figure shows 
representative images of MDA-pc3 and MDA-B6 cells at consistent locations over the period of 
six days following Cas9 transfection.  Yellow-highlighted cells represent those expressing BFP, 
while blue-highlighted cells represent those co-expressing BFP and GFP, according to the 
MetaXpress standard software settings.  Scale bar, 250 µM. 
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Figure 4.17  Effect of src knockout by CRISPR/Cas9 and validation of transfection 
A) Following Cas9 transfection, surviving transfected cells were quantified at the indicated 
time points with the ImageXpress Micro XLS microscope and the MetaXpress software.  The 
graph represents survival of transfected cells as a percentage relative to numbers of matching 
cells expressing sgRNA/BFP only.  The graph represents two independent experiments.  At 
least ten wells were analyzed per condition in each experiment.  *, P < 0.05, Student’s t-test. B) 
MDA-pc3 and MDA-B6 cells were stably transduced with the src-targeting sgRNA construct 
that also encoded the blue fluorescent protein (BFP) and selected in the presence of 2 µg/ml of 
puromycin.  The selected cells were transiently transfected with Cas9-GFP in 96-well plates 
and consistent transfection efficiency was confirmed by quantifying cells with green and blue 
fluorescence using the ImageXpress Micro XLS widefield automated fluorescence microscope 
and the MetaXpress version 6 software.  The graph represents the percentage of cells co-
expressing Cas9-GFP and BFP relative to total cell numbers per well 48 hr after transfection.  
The graph represents two independent experiments. At least ten wells were analyzed per 
condition in each experiment.  n.s., statistically not significant. 
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Figure 4.18  Confirmation of src cleavage by CRISPR/Cas9 
MDA-B6 cells were transduced with lentiviral particles containing two src-targeting sgRNAs, 
followed by transfection with Cas9.  Regions of DNA containing the src gene were PCR-
amplified from the MDA-B6 cells that had been transfected with Cas9, as well as from MDA-
B6 cells that had not been transfected with Cas9 (control).  A smaller band in the Cas9 lane 
indicates that the gene of interest was cleaved by Cas9 at both sgRNA sites (the fragments then 
recombined without the cleaved portion).  Cas9-cleaved samples were further cut by a 
Detection Enzyme (GeneArt Genomic cleavage detection kit) that cuts DNA sequences at 
insertion/deletion sites, resulting in even smaller bands if successful.  In the left-most column, a 
ladder indicates band sizes. 
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4.4 Drug Sensitivity Assays in MDA-MB-231 Cells 
SRC plays an important role in breast cancer progression and several SRC inhibitors are 
already being tested in breast cancer clinical trials (Hosford and Miller, 2014).  In order to 
model the SL interaction that was observed between SRC and EPHB6 by chemical genetics, 
various concentrations of the SRC inhibitor, SU6656, were used to treat MDA-pc3 and MDA-
B6 cells.  Consistent with the inhibitory effect of the SRC-targeting shRNA (Figure 4.14B), 
application of SU6656 showed a preferential suppression of the EPHB6-deficient MDA-pc3 
cells when compared to MDA-B6 (Figure 4.19). 
 
 
 
 
Figure 4.19  Treatment of MDA-B6 and MDA-pc3 with SU6656 
MDA-pc3 and MDA-B6 cells were cultured in 96-well plates with indicated concentrations of 
SU6656 or a matching volume of DMSO for 72 hr.  Cells were stained with resazurin and 
fluorescence was measured using a SpectraMax M5 plate reader to determine cell suppression.  
Five wells were analyzed per condition.  The graph shows percentage of inhibition relative to 
DMSO control.  *, P < 0.05, Student’s t-test. 
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cancer treatment, where it showed a relatively modest effect (Antonarakis et al., 2013).  KX2-
391 is also currently being tested for breast cancer treatment (NCT01764087) and the finding 
that there is a SL relationship between EPHB6 and SRC indicated that KX2-391 treatment 
might work more efficiently if applied specifically to EPHB6-deficient TNBC cells.  To assess 
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this possibility, MDA-pc3 and MDA-B6 cells were incubated with increasing concentrations of 
KX2-391 or a matching solvent control.  In similarity to SU6656 action, KX2-391 caused a 
significantly stronger suppression of the EPHB6-deficent MDA-pc3 cells compared to MDA-
B6 (Figure 4.20), suggesting that KX2-391 treatment may indeed potentially benefit from a 
more personalized approach, where it would be applied exclusively to EPHB6-deficient tumors.  
 
 
 
 
Figure 4.20  Treatment of MDA-B6 and MDA-pc3 with KX2-391 
MDA-pc3 and MDA-B6 cells were cultured in 96-well plates with indicated concentrations of 
KX2-391 for 72 hr.  Cells were stained with resazurin and fluorescence was measured using a 
SpectraMax M5 plate reader to determine cell suppression.  Five wells were analyzed per 
condition.  The graph shows percentage of inhibition relative to DMSO control.  *, P < 0.05, 
Student’s t-test. 
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proteins.  This resulted in four cell lines: MDA-B6-RFP, MDA-B6-GFP, MDA-pc3-RFP, and 
MDA-pc3-GFP (Figure 4.21). 
 
 
 
Figure 4.21  MDA-B6 and MDA-pc3 fluorescent cell lines 
MDA-B6 and MDA-pc3 cells were transduced with lentivirus encoding either pLD-GFP-Puro 
or pLD-RFP-Puro in medium containing 8 µg/mL polybrene.  After 24 hr, cells were selected 
with 2 µg/mL puromycin for 48 hr.  Scale bar, 100 µM.  
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For co-culturing EPHB6-expressing and EPHB6-deficient cell lines, mixtures of either 
MDA-B6-GFP and MDA-pc3-RFP, or MDA-B6-RFP and MDA-pc3-GFP were prepared.  
These cells were mixed, co-seeded in equal numbers, and treated with KX2-391 or a solvent 
control.  After 72 hr, the cells were collected and analyzed by flow cytometry in order to look 
for the prevalence of one color over the other.  This approach showed clearly that the EPHB6-
deficient cells, being either MDA-pc3-RFP or MDA-pc3-GFP, were more strongly inhibited 
than the corresponding EPHB6-expressing cell line (Figure 4.22 and 4.23).  This shows that 
even in situations where EPHB6-expressing and EPHB6-deficient cells are growing in close 
proximity, there will still be a noticeable SL effect induced by KX2-391.  This is important, as 
EPHB6-deficient tumors in patients will inevitably be found among normal tissues with normal 
EPHB6 expression.  Therefore, it is critical that the chemical inhibitors being employed have a 
stronger effect on the tumor itself, without equally inhibiting the surrounding tissues. 
 
4.5 Cell Death Assays in MDA-MB-231 Cells 
Treatment with SRC inhibitors resulted in a preferential inhibition of EPHB6-deficient 
MDA-MB-231 cells.  This result was not surprising, as SRC was found to exhibit a SL 
interaction with EPHB6.  This meant that the relative inhibition of EPHB6-deficient cells was 
likely due to an increased killing from the SL interaction.  In order to test this, cells were 
treated with KX2-391 and then stained with PI.  PI is used to stain DNA, as it binds by 
intercalating between the DNA bases.  However, PI is also membrane impermeant, and 
therefore, it is generally unable to enter healthy cells.  Because of this, increased cell killing 
results in a higher amount of PI staining, as dying cells’ membranes start to break down. 
Accordingly, it was found that KX2-391-treated EPHB6-deficient cells displayed a higher 
amount of PI staining relative to solvent-treated control cells, when compared to EPHB6-
expressing cells (Figure 4.24).  This finding indicated that inhibition of SRC caused increased 
lethality when EPHB6 expression was removed from cells. 
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Figure 4.22  Treatment of mixed MDA-B6-GFP and MDA-pc3-RFP with KX2-391 
Fluorescently-labeled MDA-B6-GFP and MDA-pc3-RFP cells were combined in equal 
numbers at indicated cell densities in 24-well plates and cultured with 25 nM KX2-391 for 72 
hr.  Cells were collected and analyzed by flow cytometry and the FlowJo software, and 
fluorescence was compared between DMSO controls and KX2-391-treated cells.  The graph 
shows ratios of proportional representation of KX2-391-treated population relative to DMSO 
control and represents analysis of triplicates.  *, P < 0.05, Student’s t-test. 
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Figure 4.23  Treatment of mixed MDA-B6-RFP and MDA-pc3-GFP with KX2-391 
Fluorescently-labeled MDA-B6-RFP and MDA-pc3-GFP cells were combined in equal 
numbers at indicated cell densities in 24-well plates and cultured with 25 nM KX2-391 for 72 
hr.  Cells were collected and analyzed by flow cytometry and the FlowJo software and 
fluorescence was compared between DMSO controls and KX2-391-treated cells.  The graph 
shows ratios of proportional representation of KX2-391-treated population relative to DMSO 
control and represents analysis of triplicates.  *, P < 0.05, Student’s t-test. 
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Figure 4.24  Propidium iodide staining of KX2-391-treated MDA-B6 and MDA-pc3 cells 
MDA-B6 and MDA-pc3 cells were cultured in glass-bottom plates in the presence of 25 nM 
KX2-391 for 72 hr.  Cells were stained for 12 min with 2.7 µg/mL propidium iodide (PI) in 
phenol red-free medium.  Cells were imaged using confocal microscopy at 200 x magnification 
and the number of PI-stained cells were counted and compared between DMSO control and 
KX2-391-treated plates.  Scale bar, 100 µm.  *, P < 0.05, Student’s t-test. 
 
 
In addition to PI staining, cells were also put through staining with 7-AAD after treatment 
with KX2-391.  7-AAD, which also binds to DNA, is also membrane impermeant and is, 
therefore, often used as an indicator of late-apoptosis.  As in the case of PI, it was found that 
MDA-MB-231 cells missing EPHB6-expression exhibited increased 7-AAD staining following 
treatment with the SRC inhibitor KX2-391 (Figure 4.25).  This provided further validation that 
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the inhibitory effect caused by KX2-391 was due to increased killing, resulting from the SL 
relationship between SRC and EPHB6. 
 
 
 
Figure 4.25  7-AAD staining of KX2-391-treated MDA-B6 and MDA-pc3 cells 
MDA-B6 and MDA-pc3 cells were cultured in 6-well plates in the presence of 25 nM KX2-391 
for 72 hr.  Cells were collected and stained with 7-AAD for fifteen minutes while covered at 
room temperature.  Cells were analyzed by flow cytometry and the FlowJo software, and mean 
immunofluorescence was compared between DMSO controls and KX2-391-treated cells.  The 
graph shows fold change relative to DMSO control and represents analysis of triplicates.          
*, P < 0.05, Student’s t-test. 
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4.6 Drug Sensitivity Assays in BT-20 Cells 
Importantly, the SL interaction observed between EPHB6 and SRC was not restricted to 
MDA-MB-231 cells alone, but were also observed in the BT-20 TNBC cell line.  Unlike MDA-
MB-231 cells, which have lost EPHB6 expression during cancer progression, BT-20 cells 
inherently retain expression of EPHB6.  Parental BT-20 cells were transduced with an shRNA 
targeting EPHB6 (BT20-B6-shRNA), or else with a non-silencing shRNA (BT20-NS) (Figure 
4.26).  This provided the opportunity to compare the SL interaction between EPHB6 and SRC 
in both a cell line utilizing EPHB6-restoration, as well as a cell line utilizing EPHB6 silencing. 
 
 
 
 
Figure 4.26  EPHB6 expression in BT-20 cell lines 
Triple negative breast cancer cells, BT-20, were transduced with an EPHB6-targeting shRNA 
(BT20-B6-shRNA), or non-silencing shRNA (BT20-NS).  EPHB6 expression was analyzed by 
Western blotting with anti-EPHB6 and quantified by densitometry.  Western blotting with anti-
tubulin was used as a loading control. 
 
 
It was important to ensure that the SL interaction between EPHB6 and SRC could be 
exploited in other TNBC cells.  Therefore, the first step was to test the SU6656 SRC inhibitor 
on the BT-20 cell lines in order to assess percentage of inhibition.  BT20-NS and BT20-B6-
shRNA cells were treated with increasing concentrations of the SU6656 SRC inhibitor and the 
resulting inhibition of cell viability was compared to corresponding solvent controls.  
Consistent with the results in MDA-MB-231 cells, application of SU6656 caused preferential 
suppression of the EPHB6-silenced BT20-B6-shRNA cells (Figure 4.27). 
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Figure 4.27  Treatment of BT20-NS and BT20-B6-shRNA with SU6656 
BT-20 cells were cultured in 96-well plates with indicated concentrations of SU6656 or 
matching volumes of DMSO for 96 hr.  Cells were stained with resazurin and fluorescence was 
measured using a SpectraMax M5 plate reader to determine cell suppression.  Five wells were 
analyzed per condition.  The graph shows percentage of inhibition relative to matching DMSO 
controls.  *, P < 0.05, Student’s t-test. 
 
 
Because the SRC inhibitor, KX2-391, has been used in phase II prostate cancer trials with 
modest effect (Antonarakis et al., 2013), and due to the fact that its use on MDA-MB-231 cells 
showed a preferential inhibition of EPHB6-deficient cells, it was important to be able to 
emulate the inhibitory effects with BT-20 cells.  This would lend further support toward the use 
of KX2-391 for patients with TNBC tumors exhibiting a loss of EPHB6 expression.  Therefore, 
BT20-NS and BT29-B6-shRNA cells were treated with KX2-391 or matching solvent control 
and then analyzed to determine percentage inhibition of cell viability.  In a similar fashion to 
treatment with SU6656, and as was observed in the case of MDA-MB-231 cell viability assays, 
KX2-391 caused a significantly stronger suppression of EPHB6-deficient BT-20 cells (Figure 
4.28). 
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Figure 4.28  Treatment of BT20-NS and BT20-B6-shRNA with KX2-391 
BT-20 cells were cultured in 96-well plates with indicated concentrations of KX2-391 or 
matching volumes of DMSO for 96 hr.  Cells were stained with resazurin and fluorescence was 
measured using a SpectraMax M5 plate reader to determine cell suppression.   Five wells were 
analyzed per condition.  The graph shows percentage inhibition relative to DMSO control.       
*, P < 0.05, Student’s t-test. 
 
 
4.7 Cell Death Assays in BT-20 Cells 
As in the case of MDA-MB-231 cells, EPHB6-deficient BT-20 cells also underwent 
increased inhibition following treatment with SRC-inhibitors.  Therefore, it was suspected that 
the BT-20 cells were also undergoing an increased killing due to the SL interaction between 
SRC and EPHB6.  To test this, BT-20 cells were also exposed to the PI and 7-AAD compounds 
following treatment with KX2-391.  As anticipated, EPHB6-deficient BT-20 cells displayed a 
significant increase of staining with PI (Figure 4.29), as well as with 7-AAD (Figure 4.30) 
following SRC-inhibitor treatment.  This indicated an increase of cell killing, which could be 
attributed to SL. 
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Figure 4.29  Propidium iodide staining of KX2-391-treated BT-20 cells 
BT20-B6-shRNA and BT20-NS were cultured in glass-bottom plates in the presence of 35 nM 
KX2-391 or DMSO for 96 hr.  Cells were stained with 2.7 µg/mL propidium iodide (PI) in 
phenol red-free medium and imaged using confocal microscopy.  PI-positive cells were counted 
in at least 10 randomly captured fields.  Counts of PI-positive cells were normalized on the total 
cell numbers in matching frames.  The graph shows the ratio of PI-positive cells in KX2-391-
treated populations relative to matching DMSO controls.  Scale bar, 100 µm.  *, P < 0.05, 
Student’s t-test. 
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Figure 4.30  7-AAD staining of KX2-391-treated BT-20 cells 
BT20-NS and BT20-B6-shRNA cells were cultured in 6-well plates in the presence of 25 nM 
KX2-391 for 96 hr.  Cells were collected and stained with 7-AAD for fifteen minutes covered 
at room temperature.  Cells were analyzed by flow cytometry and the FlowJo software, and 
mean immunofluorescence was compared between DMSO controls and KX2-391-treated cells.  
The graph shows fold change relative to DMSO control and represents analysis of triplicates.  
*, P < 0.05, Student’s t-test. 
 
 
 
 
 
 
0 102 103 104 105
B2-A: PI/LSS-mKate-A
0
20
40
60
80
100
%
 o
f M
ax
0 102 103 104 105
B2-A: PI/LSS-mKate-A
0
20
40
60
80
100
%
 o
f M
ax
1  
 
 
 
 
 
%
 o
f M
ax
 
 10
2
 10
3
 10
4
 10
5
 0 10
2
 10
3
 10
4
 10
5
 
BT20-NS DMSO 
BT20-B6-shRNA DMSO 
7-AAD fluorescence 7-AAD fluorescence 
BT20-NS KX2-391 
BT20-B6-shRNA KX2-391 
		 		
0 
1 
2 
3 
4 
5 
M
ea
n 
flu
or
es
ce
nc
e 
of
 
K
X
2-
39
1 
tre
at
ed
 c
el
ls
 
re
la
tiv
e 
to
 m
at
ch
in
g 
D
M
SO
 c
on
tro
l * 
BT20-NS 
BT20-B6-shRNA 		
	 61	
4.8 Tumor Xenograft Studies 
4.8.1 Mouse Models 
The use of SRC inhibitors to generate a SL effect in EPHB6-deficient cells proved to be 
effective in monolayer cell culture.  Lethality was observed whether the EPHB6-expressing and 
EPHB6-deficient cell lines were cultured separately, or co-seeded together.  The preferential 
inhibition of EPHB6-deficient TNBC cells continued when tested with the BT20-B6-shRNA 
cell line, showing a similar trend to that seen with MDA-pc3.  Taking this into account, it was 
determined that the SL interaction between EPHB6 and SRC might be used to target TNBC 
tumors.  In order to test this, TNBC tumors were produced in experimental animals by injecting 
MDA-B6 and MDA-pc3 cells into mammary fat pad regions of immunodeficient female 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD-SCID) mice.  These mice do not express the prkdc 
gene or the il2rg gene and are deficient in mature lymphocytes, without detectable serum Ig.  
Treatment of the animals with KX2-391 was initiated when tumors reached a detectable size 
and was then carried out until the mice had to be sacrificed in accordance with the guidelines 
established by the Animal Research Ethics Board.  Upon measurement of tumors, it was shown 
that treatment with KX2-391, indeed, more efficiently suppressed the growth of EPHB6-
deficient MDA-pc3 TNBC tumors in comparison with EPHB6-expressing MDA-B6 (Figure 
4.31).  This was important because if EPHB6-deficient tumors are to be targeted with SRC 
inhibitors in patients, there should be significantly less detrimental effect to the surrounding, 
normal tissues. 
 
4.8.2 Immunohistochemistry 
Treatment of monolayer cells with KX2-391 showed a preferential suppression of 
EPHB6-deficient cells, and the same was found to be true in the case of EPHB6-deficient 
tumors.  It has been shown that some SRC inhibitors directly affect the process of angiogenesis 
(Schenone et al., 2007).  Therefore, it was important to determine whether the inhibition of 
EPHB6-deficient tumors was due to a direct SL effect, or whether it was due to a preferential 
suppression of blood vessel formation.  Therefore, tumor sections from the xenograft models 
were stained with an antibody targeting CD34, which is a blood vessel marker.  Upon staining, 
it was found that there was not a statistically significant difference in the neovascularization of 
either EPHB6-deficient or EPHB6-expressing tumors after treatment with KX2-391.  This 
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indicated that inhibitory effect on EPHB6-deficient tumors was not related to angiogenesis, but 
was instead due to the SL relationship between SRC and EPHB6 (Figure 4.32). 
 
 
 
 
Figure 4.31  Treatment of MDA-B6 and MDA-pc3 xenograft tumors with KX2-391 
MDA-pc3 and MDA-B6 cells were injected into the mammary fat pad region of 4-6 weeks old 
NOD-SCID mice (1 x 106 cells per mouse).  Mice with detectable tumors were treated twice per 
day with 5 mg/kg KX2-391 in DMSO/water solvent or solvent alone by oral feeding (at least 6 
animals per experimental condition).  Tumor size was measured every 3 days and tumor 
volume was calculated with the equation: A/2*B2, where A was long and B was short diameter 
of the tumor.  The reduction in tumor growth in KX2-391-treated mice is presented as a 
percentage relative to matching solvent controls.  The graph summarizes two independent 
experiments.  Day 0 indicates the beginning of treatment with KX2-391 or matching solvent 
control. The experiments were terminated upon tumor ulceration according to the guidelines 
established by the Animal Research Ethics Board, University of Saskatchewan.  *, P < 0.05; **, 
P < 0.01, Student’s t-test.  
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Figure 4.32  Immunohistochemical staining of MDA-B6 and MDA-pc3 tumor sections 
MDA-B6 and MDA-pc3 tumors from mouse models were collected at day 42 after injection, 
fixed in 10% neutral-buffered formalin, and paraffin embedded.  Tumor sections were 
processed for immunohistochemical staining with anti-CD34 or stained with haematoxylin and 
eosin (H&E).  Four representative fields (at 3, 6, 9, and 12 o’clock) per each stained tumor 
section (one for each extracted tumor) were imaged at 100 x magnification and the blood vessel 
density per each field was analyzed with the Image-Pro Premier software.  The graph represents 
percentage of anti-CD34-positive area relative to the overall field of view. Images of 
representative areas highlighted by red rectangles are shown at 400 x magnification.  Arrows 
indicate representative examples of anti-CD34-stained blood vessels.  At least 6 stained 
sections per each experimental condition representing independent tumors were used for the 
analysis.  Scale bar, 500 µM.  n.s., statistically not significant. 
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5.0 Discussion 
5.1 Analyzing Significant Synthetic Lethal Hits for EPHB6 
The study of SL interactions has opened a new avenue for developing targeted therapies 
and personalized medicine.  For example, at least three clinical trials have been initiated using 
EGFR and BRAF inhibitors within three years after the SL relation between EGFR and BRAF 
was identified (Prahallad et al., 2012) (NCT01791309; NCT01750918; NCT01719380).  Such 
rapid progress into clinical trials is triggered by selective focusing on well-studied targets with 
FDA approved inhibitors.  In many cases, approved inhibitors exist for various gene products, 
but only produce a modest effect when used in clinical trials.  However, with the advent of SL 
screening, and the discovery that inhibition of SL partners can cause killing in cells that are 
otherwise difficult to treat, many inhibitors may now stand forth in a new light.  It should be 
noted, though, that even though many inhibitors may be found to be useful in the case of SL-
based therapy, some may still show a more pronounced effect than others.  This is one of the 
reasons why it is important that large-scale SL screens produce at least several significant SL 
hits. 
SL screening of EPHB6 in MDA-MB-231 TNBC cells did not disappoint, as the screen 
produced 113 statistically significant hits.  Being significant, each one of these SL hits could 
have been considered as a possible therapeutic target for preferentially killing the cancer cells.  
However, research time and funding both have limitations, and with such an abundance of 
potential targets, it was important to validate an effective therapeutic target in a timely fashion.  
There is, of course, no standard method for drawing one hit out of a pool of 113, as small as 
that number might seem compared to the total of 18,000 genes that are being targeted by 
shRNAs in our pooled library.  Therefore, determination of an appropriate target had to rest on 
several factors.  This included finding out which genes already had FDA-approved inhibitors, 
as an approved inhibitor could find its way into clinics much faster if it was shown to exhibit 
the desired SL effect.  In addition to this, analysis was carried out to determine which genes 
showed an inverse expression pattern to that of EPHB6, as this would likely indicate an 
essential compensatory mechanism when EPHB6 is lost.  These analyses revealed SRC as an 
ideal candidate for targeted therapy, and were further corroborated by study of the STRING 10 
database, which showed that SRC is a hub and highly connected to many of the other hits. 
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Based on a number of qualifiers, SRC inhibitors were then used in initial monolayer 
treatments to determine the effect of the SL interaction predicted by the screen.  Though 
experiments with SRC were successful, and the desired SL interaction was observed both in 
cell culture and in animal models, this does not discount the potential displayed by the other 
gene hits.  Some SL hits also had FDA-approved inhibitors in place, and others also displayed 
an inverse expression pattern with EPHB6.  However, this illustrates the importance of a logical 
approach to determining the best target for treatments, and such steps should be taken following 
any such large-scale SL screen.  One important reason for this is that patients require treatments 
as soon as possible, and so validation of effective targets must be carried out in a timely 
fashion.  Of course, the qualifiers to determine which therapeutic target that should be used 
depend greatly on the gene that is being screened.  Researchers would be prudent to study the 
hits produced by any given screen for some time in order to ensure that the appropriate steps are 
taken.  Additionally, future researchers would be prudent to invest time into further 
investigation of the remainder of the SL hits in order to determine the therapeutic advantages of 
each. 
 
5.2 The Role of SRC in Breast Cancer Progression 
 It is very intriguing that SRC came up as a hit in the EPHB6 synthetic lethal screen, as it 
has been known for some time that SRC plays an active role in the initiation and progression of 
a number of different cancer types.  For example, in the case of colon cancer, it has been shown 
that SRC accelerates metastasis, as well as providing a level of resistance to therapeutic drugs 
(Chen et al., 2014).  In head and neck squamous cell carcinoma and non-small cell lung 
carcinoma, SRC has been observed promoting survival of cancer cells by acting alongside 
STAT3, another known culprit in cancer progression (Byers et al., 2008; Sen et al., 2009).  But 
more importantly for this discussion, it has been found that SRC promotes the progression of 
breast cancer, with SRC activity reaching up to 20 times higher than that in normal tissues (Irby 
and Yeatman, 2000).  This is not surprising, as under normal circumstances, SRC is involved in 
the regulation of a number of pathways that ultimately moderate cell survival, proliferation, 
migration, and angiogenesis (Wheeler et al., 2009).  SRC is a tyrosine kinase that functions by 
adding phosphate groups to tyrosine residues in downstream targets, thereby activating or 
inactivating them.  However, while tyrosine kinases can be found in many of the steps in 
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different cellular pathways, SRC holds a prestigious position at the head of a number of key, 
potentially oncogenic pathways, including the STAT3, RAS, and PI3K pathways (Wheeler et 
al, 2009).  Therefore, it is no surprise that altered SRC expression levels are involved in so 
many different cancers.  For this reason, a number of SRC inhibitors are already passing 
through the different phases of clinical trials.  However, as the next section will discuss, the 
results of inhibitors until now have been modest (Antonarakis et al., 2013).  It may be that 
targeting SRC alone is not a full solution, which brings the discussion to synthetic lethality and 
interaction between SRC and EPHB6. 
 
5.3 EPHB6 Interaction with SRC 
The genome-wide SL screens discussed in this study revealed a novel genetic interaction 
between the SRC kinase and EPHB6 in TNBC cells (Paul et al., 2016).  Moreover, network 
assessment directly indicated that SRC is a central player with a high connectivity.  An 
expression analysis also showed that SRC clusters with the genes that negatively correlate with 
EPHB6 expression in various tumor types.  This indirectly suggested that SRC overexpression 
might act as an essential compensatory mechanism for the loss of EPHB6 in cancer cells, 
indicating that the SL interaction observed between EPHB6 and SRC may represent a 
promising therapeutic target.  Such a SL interaction was observed in initial experiments using 
both shRNAs and the CRISPR/Cas9 system to target SRC in EPHB6-defiecient cells, thereby 
indicating that chemical inhibitors should be the next step.  The SRC kinase inhibitor, KX2-
391, was already being tested in clinical trials, but had not yet been used in the context of 
EPHB6 expression.  Therefore, KX2-391 was used to treat both monolayer TNBC cells, and 
subsequently, TNBC tumors in mouse models of human malignancy.  In each case, the use of 
KX2-391 was shown to produce the same SL effect toward EPHB6-deficient cells that was 
observed in the initial screen.  Therefore, this investigation provides a new rationale for the 
selective use of the KX2-391 SRC inhibitor in patients that have lost expression of the EPHB6 
receptor in their tumors.  
The relevance of the findings presented here are further supported by recent unfortunate 
observations, revealing that although SRC is frequently overexpressed in cancer, in some 
clinical trials randomly applied SRC inhibition produced limited positive effects on cancer 
patients (Antonarakis, et al., 2013).  The report of the SL relationship between EPHB6 and SRC 
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may help to overcome this problem, and improve the efficiency of SRC inhibiting approaches 
in cancer therapy.  This is accomplished by showing that treatment with SRC inhibitors should 
be personalized, and mostly applied to patients with reduced or missing EPHB6 expression.  In 
this context, it was important that our analysis confirmed that small molecule SRC inhibitors 
could efficiently target the SL interaction between SRC and EPHB6.  Accordingly, our work 
revealed that EPHB6-deficient TNBC cells were, indeed, much more sensitive to these 
compounds, and were strongly inhibited relative to cells with normal EPHB6 expression.  The 
experimental data in this study suggests that EPHB6 does not protect SRC from inhibition and 
we suspect that EPHB6 most likely acts by partially compensating for the loss of the biological 
functions of the SRC kinase.  This apparent compensation also helps to explain the ability of 
EPHB6 to protect cancer cells from shRNA-induced silencing of SRC or src knockout observed 
in initial experiments.  This model fits a classical definition of a SL interaction (Dixon et al., 
2009) and provides a rationale for the limited effectiveness of SRC-inhibiting therapy currently 
observed in some cancer patients (Antonarakis et al., 2013).  
 
5.4 Building Synthetic Lethal Networks 
The research carried out in this study revealed SRC as a SL partner of EPHB6, along with 
an additional 112 significant hits.  This is useful information, as SRC inhibitors have been 
shown to preferentially kill EPHB6-deficient cells, which means that the screening 
methodology has produced a potential therapeutic strategy.  However, there are many other 
mutations implicated in cancer progression, meaning that the work carried out in this study, 
though valuable on its own, is only part of the larger picture.  It has been shown that other such 
screens have also produced a wide array of potential targets (Vizeacoumar et al., 2013).  This 
previous work also revealed that screening of SL interactions for different proteins such as 
PTEN, KRAS, and others has shown that there are often a number of hits that are in common.  
This means that these crossover hits, when targeted therapeutically, could prove to be beneficial 
for multiple cancer-related mutations.  Therefore, as SL screens are carried out for more and 
more individual mutations, it is likely that an increasing number of crossover hits will be found 
(Figure 5.1).   
Although each individual screen, such as the EPHB6 screen, is valuable on its own, much 
more similar work would need to be carried out on many different genes mutated in cancer.  
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Such findings would help to build a much larger network of NGIs for different cancer 
mutations, as well as the many therapeutic targets that are in common between different genes 
families.  Of course, this would require large collaborative efforts within the cancer research 
community, as screening for one gene alone, as well as the subsequent examination and 
validation of SL therapeutic targets is a substantial amount of work.  However, armed with such 
knowledge, medical professionals would be able to use the genetic profile of individual tumors 
to increasingly greater success.  As it now stands, the scientific community has already learned 
a great deal about the various mutations that are involved in cancer, as well as the many ways to 
provide appropriate therapies.  However, with the construction of a comprehensive interaction 
map of cancer-causing genes, and their SL partners, the ability to develop patient-specific, and 
even tumor-specific therapies will become increasingly viable.  In time, it may even be possible 
that such SL interaction maps will generate therapies for many of the cancers for which painful 
and uncomfortable strategies such as chemotherapy, radiation therapy, and surgery are the only 
options.  In fact, with more personalized therapies, less patients may have to be exposed to such 
broad-spectrum strategies altogether.  All told, a collaborative construction of a SL interaction 
map for cancer genetics would be a boon for both doctors and patients, and would provide a 
strong platform for further cancer research.  
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Figure 5.1  Building synthetic lethal networks 
As genetic interactions are confirmed between various genes in a given biological process, sub-
interaction networks begin to emerge.  Such interactomes, or E-MAPs (epistatic mini array 
profiles), are networks of query genes (nodes represented with alphabets) that relate to 
particular cellular systems, such as metabolism, signaling, transcription, translation, or others.  
Within each E-MAP, potential gene targets (synthetic lethal partners – depicted as tiny nodes) 
are determined to be synthetic lethal partners.  As more of these E-MAPs are generated, 
common synthetic lethal partners from each can be found (nodes represented in numericals), 
thereby pointing to therapeutic targets for cancer treatment on a whole-cell level.  
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6.0 Conclusions and Future Work 
6.1 Conclusions 
In the past, SRC inhibitors have been used to treat different cancer types, albeit, with 
varying degrees of success.  The findings reported here indicate that a more selective 
application of SRC inhibitors may be necessary, as opposed to the broad application that has 
been utilized thus far.  These observations indicate that EPHB6 may be efficiently used as a 
biomarker for selecting exclusively EPHB6-deficient TNBC tumors for the treatment with SRC 
inhibitors.  This means that, due to the SL relationship between SRC and EPHB6, SRC 
inhibitors may only be beneficial when tumors display a decrease of EPHB6 expression.  Such 
a discovery might even begin to explain why treatment with SRC inhibitors has only had 
modest effects; as such treatments have not previously been used in the context of EPHB6 
expression.  Such a personalized approach is likely to increase the chance of success when 
utilizing SRC inhibitors for TNBC treatment.  Additionally, this model may also potentially be 
applicable to multiple other tumor types, where EPHB6 expression is reduced according to 
previously published observations and according to the findings reported here.   
There are other reasons why EPHB6 is important as a biomarker for SRC inhibitor 
treatment.  An equally important outcome of this research is that it would also benefit patients 
with EPHB6-positive TNBC by preventing their involvement in ineffective treatment protocols.  
SRC inhibitors have been used in the past with varying degrees of success, which means that 
some patients have been involved in such treatment strategies without necessarily seeing the 
desired outcome.  In the case of cancer treatment, time may often be a limiting factor, and the 
ability to apply effective treatments is of paramount importance.  Therefore, with the 
knowledge that EPHB6 is a biomarker for SRC inhibitor treatment, patients with high EPHB6 
expression in their tumors would be able to avoid using a potentially ineffective treatment 
strategy, while being directed to more appropriate therapeutic options.  This would help to 
prioritize the time that is available to patients battling cancer, and would additionally prevent 
any possible adverse reactions to drugs that may not be beneficial in their case anyway.  
Furthermore, appropriate use of SRC inhibitors based on EPHB6 expression would decrease 
unnecessary application of drugs by the health care systems involved, thereby saving resources 
for other endeavors. 
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In addition to the findings pertaining to EPHB6 and its importance in regard to 
prioritization of SRC inhibition strategies, there are other important findings revealed in this 
research.  This investigation utilized a genome-wide SL screen in order to finding targetable 
weaknesses in an otherwise deadly cancer type.  Screening was followed by a successful 
validation of its results, both in cell culture and in an animal model of human malignancy.  This 
shows the value of large-scale SL screening, as one such screen can produce both immediate 
therapeutic options (as in the case of SRC inhibitors), as well as many other possible targets for 
future research.  In addition, even though TNBC is normally untargetable due to the inherent 
loss of ER, PR, and lack of HER2 overexpression, the research presented here has shown that 
methodologies such as large-scale SL screening are able to produce alternative therapeutic 
targets.  This is valuable as it presents other options to patients, rather than simply being forced 
to resort to more broad or invasive strategies.  Therefore, this provides a strong support for the 
use of such a methodology in finding new therapeutic targets and developing personalized 
treatment approaches.   
 
6.2 Future Work 
The research presented here naturally lends itself to several avenues of future work.  First, 
the pooled screen identified a total of 113 genes that were shown to be SL with EPHB6 in 
TNBC cells.  This means that even though SRC was found to be strong candidate for SL 
killing, future studies may benefit from following up on a number of the other hits that were 
found.  This would be straightforward to do as many of the hits already have chemical 
inhibitors in place.  In addition, it might even be shown that multiple SL hits may be targeted 
together for effective killing of EPHB6-deficient TNBC cells.  However, this need not be 
confined to TNBC alone, as the SL relationship between EPHB6 and SRC may extend to other 
cancer types as well.  Therefore, SRC inhibitors should be used on other types of cancer 
exhibiting known EPHB6 loss, starting with tissue culture conditions, and moving to animal 
models if results prove favorable.  This might broaden the range of uses for SRC inhibitors, 
while simultaneously providing new treatment options for patients with other cancers besides 
TNBC.  Of course, in order to ensure the efficacy of this treatment strategy for actual patients, a 
further evaluation of EPHB6 function in freshly obtained tumor samples would be necessary.  
Lastly, in addition to the screening of EPHB6, other large-scale screens should carried out, 
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particularly in the case of genes that are lost during cancer progression, as these deficiencies are 
otherwise difficult to treat due to the lack of function products to target.  This screening could 
continue to utilize shRNA libraries, or other methods such as CRISPR/Cas9 analysis could be 
brought to bear.  This would require a large scale CRISPR library, with sgRNAs targeting all of 
the genes that are covered by the current shRNA library used in this research.  However, the 
results may exhibit great precision, as the CRISPR/Cas9 system results in knockout at the 
genomic level. 
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